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Introduction 
The power and influence of genetic testing is demonstrated in a case that involved a 
three-year-old male with a pregnant mother who came in to a genetic counseling clinic with 
symptoms of Mucopolysaccharidosis type II (MPS type II); also known as Hunter’s 
syndrome. This disease is caused by a deficiency in the lysosomal enzyme iduronate 2-
sulfatase which leads to a buildup of glycosaminoglucans in cells all over the body and almost 
exclusively affects males. The effect of this is abnormal development during key formative 
years and begins to show around ages 2-4. Patient’s exhibit troubled breathing, swelling, 
skeletal malformations and neurological degeneration. Most patients with this disease only 
live until around age 20 with treatment.1 MPS is an X chromosome linked disease meaning 
the mother carries the mutation but, in this case, does not experience symptoms herself 
because of her second X chromosome. After diagnosis of the child, the mother was tested and 
found to be a carrier of the disease meaning she had a 50% chance of passing on the disease 
to her next male child. The mother was in fact thirty-four weeks pregnant at the time of 
diagnosis with another male child. The fetus was also tested and found to be affected by the 
disease. After deliberation, the parents chose to carry out the pregnancy but gave up the 
                                                          
1Wraith, J. Edmond, Maurizio Scarpa, Michael Beck, Olaf A. Bodamer, Linda De Meirleir, Nathalie Guffon, 
Allan Meldgaard Lund, Gunilla Malm, Ans T. Van der Ploeg, and Jiri Zeman. 2008. 
“Mucopolysaccharidosis Type II (Hunter Syndrome): A Clinical Review and Recommendations for 
Treatment in the Era of Enzyme Replacement Therapy.” European Journal of Pediatrics 167 (3): 267–77. 
doi:10.1007/s00431-007-0635-4. 
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child for adoption because of the disease and treatment began on both children at the same 
clinic. Unexpected findings from genetic testing has a huge impact in the lives of patients. 
This is the reality that many patients who undergo genome sequencing face and it is a 
problem that researchers of genetics and clinicians alike must address.  
Stories like this show the importance and power of genomic data in the lives of 
everyday individuals. The mother was made aware of her unborn child’s condition because 
of incidental findings that affected her and the child. Next-Generation Sequencing is the 
latest and most widely used series of techniques by researchers and clinicians alike to study 
heritable diseases like MPS. Genome sequencing allows researchers to narrow down the 
problem in the genome which translates into various things down the line like individual 
proteins or organ development. Easy genomic testing did not come about until 1977 with the 
advent of Sanger sequencing. First generation technologies like this allowed for researchers 
to slowly test aspects of a genome. It was not until 2005 with the Genome Analyzer that 
allowed for sequencing runs to go from 84 kilobase per run to 1 gigabase per run that easy 
genome sequencing was possible. This was the start of the “Next” generation of sequencing. 
The first human genome to be sequenced and published was in 2001 and took 15 years and 3 
billion dollars to complete. By 2014, the cost for an individual’s genome to be sequenced 
dropped to 1000$ and can be done in a single day.2  
                                                          
2 “An Introduction to Next-Generation Sequencing Technology.” 2016. 
http://www.illumina.com/content/dam/illumina-
marketing/documents/products/illumina_sequencing_introduction.pdf. 
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Genetic information is becoming more widely used and it has many applications that 
go beyond diagnosing a single disease in an individual. Because we have the ability to 
analyze the entire set of an individual’s genetic information even though we are looking for 
something specific, there is the chance of finding other problems. These other problems that 
we find have the ability to severely affect the patient whose genome we are sequencing. For 
example, if we found out a patient is likely to experience a deadly heart condition or cancer 
in the future while searching for an unknown metabolic disorder. These possible findings are 
called secondary findings and are an ever-increasing issue in in the field of genetics. 
Secondary findings are findings that concern a patient’s health or are reproductively 
significant that are not under the scope of the research being conducted.3 Issues surround the 
ability for researchers to fully inform patients as well as addressing the uncertainty of 
developing a disease; even with mutated genes. A large part of the discussion is about the 
diseases and genes that should be included or not when reporting back to patients with the 
final analysis. There is also the issue of calculating the severity of the diseases that should be 
included within reports. These are some of the questions that must be addressed when 
discussing secondary findings.  
 I will argue that the best approach for researchers and research institutions when 
dealing with secondary findings is to develop an ease of information so that patients are fully 
                                                          
3 Wolf, Susan M, Brittney N Crock, Brian Van Ness, Frances Lawrenz, Jeffrey P Kahn, Laura M Beskow, Mildred 
K Cho, et al. “Managing Incidental Findings and Research Results in Genomic Research Involving Biobanks 
and Archived Data Sets.” Genetics in Medicine : Official Journal of the American College of Medical Genetics 
14, no. 4 (April 2012): 361–84. doi:10.1038/gim.2012.23. 
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informed going into genetic analysis. The autonomy of the patient is incredibly important 
when dealing with requesting secondary findings and in almost all cases, the decision of the 
patient is final. Within this thesis, I will be recommending where and how to present 
secondary findings to patients and to the Rare Genomics Institute (RG) that works with rare 
disease patients from all across the country. I will be recommending genes from the 
American College for Medical Genetics secondary findings list as well as my own research to 
be included within these secondary findings reports. The goal is to provide a useful and 
comprehensive recommendation for RG to start reporting secondary findings to patients so 
that they will be even more helpful to patients who contact this non-profit research 
institution.  
Patients often seek help in a medical clinic, where a clinician communicates with 
genetics counseling institutions like RG or guides the patient to contact these institutions 
themselves. Patients are then recommended a genetics counselor that helps the patient get 
sequenced. After sequencing and initial analysis, the genomic data is sent to these 
institutions for further analysis. Institutions like RG pass along the information to registered 
volunteers who comb through the data of a patient in order to report back to the institution 
which then contacts the patient or the patient’s clinician. This relationship complicates 
ethical analysis because volunteers are not medical professionals but are effectively held to a 
high standard. Volunteers are given the patient’s exome as well as the immediate family’s 
exomes and are the primary data miners. They give their findings to the institute with the 
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recommendation to report or not. In a non-reported case, the results are generally 
inconclusive as one or two variants were not deemed to be primarily causative in the patient. 
Volunteers use databases like Omicia Opal and OMIM (Online Mendelian Inheritance in 
Man database) to analyze the results and reactions of mutations. Omicia comes with analysis 
from other databases as well as its own score on the whether a mutation is likely to be 
deleterious or not named the Omicia score. This score lies between 0.00 and 1 where the 
higher integers indicate likelihood of deleteriousness. Each gene has an Omicia score and the 
database allows for sorting via Omicia score and other factors that indicate deleteriousness in 
a gene.  
Through these indicators, geneticists and volunteers determine the chances of a gene 
being causative and report this kind of information. The responsibility of relaying the 
findings of the researchers to the patient is the patient advocate or clinician and informed 
consent is usually obtained this way as well. Clinicians are often grouped with genetics 
researchers in discussions on secondary findings, however they maintain a distinctly separate 
role. Clinicians act as a middleman that help patients be informed and sometimes keep 
contact with the researching institution. The primary party responsible for the ethical 
foundations and work are the researchers who take the genomic information to analyze. 
They are the ones responsible for informing the patients and protecting the information 
gathered.  
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There is a broad discussion over the significance of secondary findings and whether 
researchers are required to report these findings. The general consensus amongst clinicians, 
researchers and patients is that these findings should be made available to the patient but 
many problems exist between the actors in this ethical quandary.4 From the patient’s 
perspective, there is the question of the rights of autonomy that exist between the 
information that researchers can provide and future problems that could be mitigated from 
this knowledge. Informed consent also creates a situation between patients and researchers 
where it is the researcher’s responsibility to fully inform the patient to the best of their 
ability, with or without the help of a consulting clinician. There is also the issue of what 
researchers would be required to report if they are required to at all. Whole exome 
sequencing is limited in its ability to definitely pin a cause to certain diseases as it is only 
about 1-2% of the total genome. Recent research has also indicated that the exome is not the 
only part of the genome responsible for problems, demonstrating that whole exome 
sequencing is limited in some significant ways. The criteria for causative mutations are still 
being researched so choosing which genes to report is a tremendous scientific task. Some 
institutions like the Rare Genomics Institute, do not currently engage in secondary findings 
which effectively rob patients of valuable information that could contemporarily be 
presented to them. Through informed consent, respect for autonomy and critical gene 
analysis these institutions can effectively provide a means for patients to maximize the 
                                                          
4  Klitzman, R, P S Appelbaum, A Fyer, J Martinez, B Buquez, J Wynn, C R Waldman, J Phelan, E Parens, and W 
K Chung. 2013. “Researchers’ Views on Return of Incidental Genomic Research Results: Qualitative and 
Quantitative Findings.” Genet Med 15 (11): 888–95. doi:10.1038/gim.2013.87. 
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effectiveness and beneficence of genome sequencing. As a primer for the rest of the thesis, 
this next chapter is a quick overview of genetics that the reader will need to understand later 
chapters. 
 
An Introduction to Genetic Analysis 
Hereditary diseases are a result of malfunctions in the complicated machine that is a 
human being. DNA (Deoxyribonucleic Acids) is the foundation of this machine and genetics 
as a whole. Hidden within DNA is the code that tells the cogs within the machine how to 
develop and work; it is the blueprint of the human organism. We knew that DNA was the 
blueprint for organisms but the structure of DNA was not discovered until 1953 when James 
Watson and Francis Crick published a paper in Nature on the subject with heavy influence 
from Rosalind Franklin.5 The blueprints turned out to be only four nucleotides, equivalent to 
four letters. The four letter code that makes up DNA was not broken until 1960s when 
scientists like Marshall Nirenburg and Johann H. Matteai discovered how information was 
stored in these strands.6   
 
 
                                                          
5 “Franklin, Watson &amp; Crick.” 2010. 
http://virtuallaboratory.colorado.edu/Biofundamentals/labs/WhatisScience/section_08.html. 
6 “Timeline: History of Genomics.” 2016. Wellcome Genome Campus. http://www.yourgenome.org/facts/timeline-
history-of-genomics. 
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The blueprints are read in triplets, like CAT or TAG, which code for different amino acids. 
Amino acids are the next building block which come together to make up proteins. One can 
think of proteins as the tiny cogs in the human machine. There is an incredible number of 
these cogs within the human machine and the DNA blueprints that buildup everything else 
are essentially organized into sections called genes.7 Genes are long sequences of those 
triplets which can be tens of thousands of letters long. Genes are divided into two different 
sections considered coding and non-coding parts of the gene; like usable and non-usable 
parts. Exons are the parts of the gene that remains after certain parts of the transcripted gene 
are cut out. Exons are the protein encoding parts of the DNA and are essential in both life 
and medical research and the total combination of exons is called the exome. This contrasts 
with the genome, in that, the exome is the protein coding parts of the DNA and the genome 
is the entire set of DNA; coding and non-coding parts.  
                                                          
7 “An Overview of the Human Genome Project.” 2015. National Human Genome Research Institute. 
https://www.genome.gov/12011238. 
 
Figure 1: Chimera representation of B-
Deoxyribonucleic Acid (DNA). The red 
and blue strands are the backbone of 
the molecule. The central rectangles 
represent the four sugars equivalent 
to the letters A, T, C, G.  
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The genome is packed into every cell and the genome itself is divided into 23 pairs of 
compact DNA called chromosomes. If we are thinking about machines, then chromosomes 
can be compared to essential car parts where one chromosome would code for the different 
parts of the engine in a car and another would code for the parts that make up the tires. 
Chromosomes are more complicated than this in that one chromosome could have parts of 
the engine, tires and transmission within it. One missing pair of chromosomes and the car 
cannot be completed. All cells have two copies of each chromosome inheriting one from 
each parent. The parents produce haploid gametes which are cells that only have one copy of 
each chromosome. Each copy of the chromosome inherited from the parents differs slightly. 
What people know as traits are the outward expression of the genes on these chromosomes 
like the color and form of the car. Traits are known to be recessive or dominant where 
recessive traits are those that result of two abnormal alleles being inherited. Dominant traits 
are those where only one allele is necessary to exhibit the trait so for example, brown eyes 
are more common in the general population because the alleles that encode for brown eyes 
are dominant. An allele is a variant form of a gene which is brought about by mutations. 
Some mutations are benign and do not change the function of the protein coded by the gene 
whereas others are problematic and change or eliminate the function of the protein coded by 
the gene. If one copy of a chromosome within an individual has a deleterious mutation, there 
is usually another copy with the non-mutated gene that corrects for the mistake. If someone 
inherits two of the same allele with the same mutation in both of the inherited 
chromosomes, then it is known as homozygous. If someone inherits two different, 
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deleterious mutations then it is known as compound heterozygous. These mutations 
sometimes manifest themselves as hereditary disorders and are the motivation for medical 
genomic sequencing which brings about the topic issue of secondary findings.   
Patterns of inheritance are how genes with mutations in them get passed down onto 
the next generation. Autosomal dominant means only one mutated form of the gene needs to 
be present to cause the disease whereas two mutated genes need to be present for autosomal 
recessive inheritance. X-linked inheritance is affected by dominant and recessive inheritance 
but is also the only chromosome that is sex dependent which affects who may experience the 
disease. If a male inherits a mutated gene on the X chromosome, they do not have another 
copy like females do to correct for the non-functional protein. Somatic mutations are 
mutations that occur after conception and multifactorial inheritance means that many factors 
play into whether the disease is present or not. Multifactorial inheritance can be a 
combination of genetic and environment factors so the disease may not be entirely genetic. 
Modern methods of genomic sequencing highlight entire exomes or genomes which 
are invaluable to researchers, clinicians and patients.89 New Generation Sequencing (NGS) is 
sweeping the market of genomic sequencing leading to lower costs and more availability for 
                                                          
8 Appelbaum, Paul S., Erik Parens, Cameron R. Waldman, Robert Klitzman, Abby Fyer, Josue Martinez, W. 
Nicholson Price, and Wendy K. Chung. “Models of Consent to Return of Incidental Findings in Genomic 
Research.” Hastings Center Report 44, no. 4 (2014): 22–32. doi:10.1002/hast.328. 
9 Olson, S, S H Beachy, C F Giammaria, and A C Berger. Integrating Large-Scale Genomic Information Into 
Clinical Practice: Workshop Summary, 2012. 
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researchers and medical professionals.10 The ability to sequence an entire genome the size of 
humans is only a recent development. Frederick Sanger sequenced the first genome of a virus 
in 1977 and the first disease associated gene was found in 1983. The Human Genome Project 
was launched in 1990 with the goal of sequencing and mapping all the genes within humans 
and this goal was completed in 2003.11 This lead to comparable collections of human 
genomes like the 1000 Genome Project which researchers use as templates for genetic 
study.12 The culmination of sequencing technologies has allowed clinicians and researchers 
to analyze a patient’s genome within just a few months. Analyzing a subject’s entire genome 
allows genetics professionals to establish the precise causes or influences of certain diseases. 
Similarly, whole exome sequencing provides another tool in establishing these causes and is 
an easier way to determine causative DNA mutations. There is a vast quantity of data that 
genome sequencing creates which researchers and clinicians must sort through which creates 
the issue of secondary findings. This takes many forms from pharmacogenetics to genetic 
counseling where many fields conduct research using whole genome and exome sequencing. 
The problem is two-fold in how we should approach secondary findings and what should we 
report to patients. The object of this thesis is to explore and recommend ethical issues 
surrounding secondary findings for genetic researchers at the Rare Genomics Institute and to 
                                                          
10 Morozova, Olena, and Marco A. Marra. “Applications of Next-Generation Sequencing Technologies in 
Functional Genomics.” Genomics 92, no. 5 (2008): 255–64. doi:10.1016/j.ygeno.2008.07.001. 
11 “All About The Human Genome Project (HGP).” National Human Genome Research Institute, 2015. 
https://www.genome.gov/10001772. 
12 “Timeline: History of Genomics.” 
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others that provide services to patients with rare genetic diseases; as well as suggest which 
genes should be considered in patient reports. 
 Next Generation Sequencing is expanding the field of genetics at an incredible speed 
but at the current time there are still many limitations that we as researchers are bound by 
and affect reporting secondary findings. NGS sequencing is still a relatively new technology 
so there is a limit on the knowledge that researchers have on the genome and genes 
themselves. Not everything is known about some genes like how they function and interact 
with other genes. Oftentimes databases will mark mutations in a gene as a “variant of 
unknown significance” which is just a mutation whose ramifications are yet unknown to 
researchers. Research and scientists are not always correct in their analysis and problems can 
develop in reporting secondary findings from simple mistakes. Unknowingly reporting that a 
certain mutation within a gene is benign when in reality it has deleterious effects could be a 
severe mistake to report to patients. It is not unknown for the significance of a mutation to 
change from benign to pathogenic or vice versa. Databases can compound this problem like 
Clinvar. Clinvar is a free use database that reports relationships among human variation and 
phenotypes with supporting evidence. Clinvar works by integrating multiple other databases 
and allows for researchers to report their data. The problems that arise from this aggregation 
of sources is that other databases may misreport the pathogenicity of a mutation which then 
shows up in Clinvar and pathogenicity reports. Because Clinvar is free it may discourage 
researchers from further studying whether a specific mutation is pathogenic or not which 
15 
 
could spread misinformation. Databases like Omicia Opal also have problems that stem from 
its operations. Omicia is a comprehensive analysis tool for exomes and whole genomes which 
show the entire exome and can be compared to others. Omicia uses databases like Clinvar 
and COSMIC for its own evaluation of the deleteriousness of gene called the Omicia Score. 
Institutes like RG use Omicia Opal for much of their analysis and if other aggregate databases 
are wrong about a gene then the misinformation may be given to patients as diagnoses. A lot 
of questions surrounding secondary findings stem from these uncertainties but the likelihood 
of these database problems is very low and the databases are a great and expediting tool for 
genetic analysis that benefits the process of genetic analysis.  
 
Informed Consent  
Obtaining permission from the patient is the first incredibly important step when it 
comes to analyzing their genomes. Genetic information can be stored indefinitely and can be 
reevaluated after new genetic discoveries.  Storing genetic data is invaluable for researchers, 
clinicians and patients alike and there are many ways organizations are storing this kind of 
data. The Personal Genome Project is a research project devoted to sharing genomic data for 
these reasons for the benefit of patients and research.13 Patients are also likely to want 
discloser of secondary findings or data that is relevant to family members. The genome of 
one individual can help warn of risks for both that patient and other members within their 
                                                          
13 Lunshof JE, and Ball MP. “Our Genomes Today: Time to Be Clear,” 2013. doi:10.1186/gm52. 
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immediate family. There are many possible approaches for patients after they sequence their 
genome however it is often an uphill battle in informing patients to an acceptable degree 
where they understand what is being asked of and done with their genetic data.  
Informed consent is the autonomous and informed authorization by the patient for 
participation in research. Clinicians generally have the closest contact with the patients and 
their families which, at least on the surface, puts the responsibility of informed consent on 
the shoulders of the practitioner clinician. Informed consent is the condition of a patient or 
subject having substantial understanding of the process and autonomously authorizes 
professionals to work with them.14 As an ethical standard for medicine, informed consent is 
necessary when analyzing an individual’s genetic information. Basic moral concepts that 
surround the issue of informed consent being; nonmaleficience, beneficience, justice, and 
respect for autonomy. The general approach to many medical decisions is being as ethical as 
possible when dealing with patients. This approach has been modified from the Hippocratic 
Oath and is the general principle of doing no harm15 which is the core of nonmaleficience. 
The express goal of clinical work and medical research is to help patients and stop whatever 
harm has befallen them. Similarly, the principle of beneficence is the notion that there is an 
obligation to act for benefit of others, and in this case patients, and justice is the right to this 
treatment.16 The principle of justice is all about the access to healthcare and information. 
                                                          
14 Beauchamp, Tom L., and James F. Childress. Principles of Biomedical Ethics: Fifth Edition. Oxford University 
Press, 2001. 78. 
15 Beauchamp and Childress, Principles, 114 
16 Beauchamp and Childress, Principles, 166, 226 
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With this principle, it is important to provide as much information to the patient as possible, 
within reason, which is why secondary findings should always be offered. In ignoring 
secondary findings, institutions are not doing the patient any justice by robbing them of 
valuable information. These are ethics principles that are going to be assumed to be standard 
regarding secondary findings.   
The importance of informed consent is evident in the problems that have arisen in 
the past from unethical medical and research practices. In 1958, a pancreatic enlargement 
patient that entered medical care and was recommended by the practitioner to have a 
cystoscopic exam. After this exam, the practitioner recommended a transurethral prostatic 
resection the next day which makes the patient sterile. The patient was not informed of the 
resulting sterilization before the procedure and sued the hospital in the famous Bang vs. 
Charles T. Miller Hospital case.1718 This case demonstrates the consequences of a severe 
breach in informed consent. In less extreme cases, there is still a difference between 
adequately informed and fully informed. This poses a unique problem where a patient should 
clearly be fully informed of the medical professional’s intentions but there may be situations 
where practitioners and researchers can only adequately inform a patient, especially on 
secondary findings. It may be impossible or impractical to fully inform certain patients on 
secondary findings with regards to genetics and inheritance probabilities. One piece of 
information can influence whether a patient understand the consequences or not. Patient 
                                                          
17 “Bang v. Charles T. Miller Hospital Case Brief,” 2014. http://www.lawschoolcasebriefs.net/2014/01/bang-v-
charles-t-miller-hospital-case.html. 
18 Beauchamp and Childress, Principles, 88 
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understanding of genetics and biology varies considerably in the general population and 
there are people with an incredibly limited knowledge of these topics. Illiterate patients pose 
a standard problem for researchers looking to obtain informed consent and must rely on the 
practitioners to adequately get information across to these patients. It may also be impossible 
to fully inform patients in a philosophical sense where a patient cannot fully understand the 
process but this extreme notion is merely speculation. Patients benefit more from having 
knowledge available to them and those conducting research are ethically responsible for 
attempting to fully inform patients. While patients may not have the necessary experience to 
use the data themselves, there are experts in the field of genetics and medical clinics devoted 
to the interpretation of genomic information.19  Genetic counselors are specialists devoted to 
the interpretation genomic data and clinical care of afflicted patients. Patients should be told 
of how to approach further genetic testing if they so desire from either the research consent 
forms or the clinicians. One targeted genetic test is not comprehensive, even with the 
inclusion of a secondary findings report. Because these reports are only the shallowest probe 
into problematic mutations, they should not be the end all for genetic testing which is why 
patients should be presented with options where they can bring the information they 
received from the initial genetic test.  
Patients have different priorities and perspectives when they seek genetic counseling. 
One of the oft cited concerns of patients is privacy with regards to their genomic 
                                                          
19 Olson et al, Integrating, 7-10, 18-19. 
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information.20 One aspect of informed consent is about being within legal boundaries and 
knowing laws that affect patients and researchers. Current cultural movements have 
emphasized privacy and genetic data is known to be an identifier concerning some patients. 
In 1983, the US President’s Commission for the Study of Ethical Problems in Medicine and 
Biomedical and Behavioral Research prioritized confidentiality of genetic data over that of 
autonomy.21 While NGS technologies have made it much easier for more people to be 
sequenced in recent years, the subject of ownership of genetic data and privacy has only 
been touched upon by the United States Federal government. In May 2008, the United States 
legislative branch passed the Genetic Information Nondiscrimination Act (GINA) guided by 
the Office for Human Research Protections and the Department of Health and Human 
Services. GINA prohibits discrimination of an individual in health insurance and 
employment based on genetic information.22 Health insurers are restricted from requiring 
genetic information from an individual or their family as well as restricts using genetic 
information for coverage or policies. Employers are also restricted in the same manner where 
they are prohibited from requiring genetic information in all aspects of employment and may 
not terminate, hire, or influence promotions based on genetic information.  
One area that is heavily influenced by GINA are the reporting of secondary findings. 
Clearly health insurance companies have a lot to gain from using genetic information in 
                                                          
20 Olson et al, Integrating, 21. 
21 Lunshof and Ball, Our Genomes Today: Time to Be Clear 
22 OHRP, and DHHS. “Guidance on the Genetic Information Nondiscrimination Act: Implications for Investigators 
and Institutional Review Boards” March 24 2 (2009): 7. 
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making a decision on whether to insure to cover a patient who may be susceptible to 
hereditary diseases. Clearly, again, this poses an enormous issue for patients seeking health 
insurance and the patient-researcher relationship is the topic of this thesis. One issue in 
genetics testing is that mutations in certain genes are not guaranteed to lead to issues. These 
variants of uncertain significance are not guaranteed to be problematic so even though a 
patient has a mutation in that gene, it may not be deleterious or problematic. The 
understanding of deleterious mutations is still far too underdeveloped to be used as a 
deciding factor in insurance or employment. Employers may discriminate against employees 
or applicants because of their susceptibility to hereditary diseases which could take them out 
of workplace earlier than the employer desires. Secondary findings that would affect 
insurance or employment would be a huge concern for anybody obtaining genetic testing 
and would likely lead to more people rejecting these findings which are important for the 
future health of an individual. GINA is praised as being a baseline of protection against 
discrimination from genetic testing, however this law does not apply to employers with 
fewer than 15 employees, the military, and does not cover long term coverage, life insurance 
or disability insurance.23 Knowing the legal situation surrounding genetic information may 
be important for patients seeking genetic testing which may discourage them from getting 
secondary findings. Using genetic information to discriminate against individuals is 
contentious because the current knowledge of genetics is not definite and many connections 
                                                          
23 “Genetic Discrimination and Other Laws.” National Human Genome Research Institute, 2014. 
https://www.genome.gov/10002077#al-3. 
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need to be described between genes. A mutation of unknown significance found on the 
BRCA2 gene may be benign but would still show up in a secondary findings report which a 
life insurance company may use as a determining factor in their coverage decision.  
From an ethical perspective, discrimination based on genetic information 
disadvantages people based purely on what they have inherited. Similarities can be drawn to 
the discrimination based on race where both are aspects of a person’s life that they never 
controlled. Knowing an individual’s genetic information would be beneficial for the business 
practices of insurance companies and employers and there are still some loopholes for 
companies to use genetic information against people. Insurance and employment are two 
essential commodities in the contemporary United States that would likely be in jeopardy if 
GINA were not enacted.  While this bill is a step in the right direction, GINA is only 
considered a minimum basis for protection of genetic information and many states have their 
own laws regarding genetic privacy that research institutes must be aware of.24 More 
protections should be given to people based on their genetic information. In the case of 
genetic information protection from federal law, all information that is pertinent to the 
patient needs to be relayed. Patients will need to have enough information to make an 
autonomous decision and should know the exceptions to GINA. Certain exceptions may 
apply to a patient and it is up to the patient to decide whether they would like secondary 
findings reported; even if it means jeopardizing their chances of insurance or employment 
                                                          
24 OHRP and DHHS, Guidance, 1. 
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because of current laws. If they are employed by a small business with less than 15 people or 
disability insurance important to their livelihood or family, they should be informed that 
their genetic information is not guaranteed to be protected under federal law. The cost-
benefit of reporting secondary findings in that kind of scenario may be too great even if 
finding out future problems would be beneficial for them. Federal law is the depth that 
institutes like RG can inform the patient of whereas the clinician or genetic counselor will be 
more familiar with state laws regarding the privacy of genetic information. The clinician and 
researchers both provide an important contribution when it comes to giving the patient 
enough information for them to access their situation and make an autonomous decision.  
The GINA definition of a genetic test includes analysis of human DNA, RNA, 
chromosomes, proteins or metabolites as well as tests detecting mutations, genotyping or 
chromosome changes.25 Clearly this applies to genetic testing for hereditary diseases that 
patients come to Rare Genomics for. Patients should be informed of the laws that apply to 
genetics testing which is different for every state, however this is difficult for national 
research institutions. This is best left for clinicians and the genetic counselors who have 
direct, face-to-face contact with the patient. At the minimum, it is a responsibility of the 
researchers to inform patients of federal laws that apply to their genetic information.  
A quick summary of GINA and the exceptions of this law should be discussed with 
the patient before genetic sequencing or in a release form; both for informed consent and 
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providing autonomous choice. In a study done by Simon et al. on disclosing individual 
research results (IRR) and informed consent processes, only 10 of a sample of 45 documents 
on IRRs and secondary findings included references to GINA.26 If researchers do not 
reference the legal protections of a patient within the informed consent process, then 
veracity is lost. Veracity is essentially the respect for a patient’s autonomy and a sense of 
justice. Researchers have an obligation from their position of power to act in the best 
interests of the patients which is bolstered by a sense of veracity. This obligation being 
comprehensive, accurate and objective transmission of information to the patient. The 
professional also fosters an understanding in the patient and this obligation is only non prima 
facie when it conflicts with other obligations that the professional has. Information is prima 
facie with patients but this may be complicated if patients are deemed incapable of handling 
certain information. The hypothetical situation here would be if anxiety is a serious factor in 
fully informing the patients of secondary findings. Presumably patients would desire to hear 
the secondary findings report after they have made the autonomous decision to have them 
reported with the genetic test, however they may change their mind in the interim period or 
prove incapable of handling information. Should researchers find deleterious mutations in 
the list of scanned genes that could prove serious, there is an argument to be made for 
informing the family but keeping the information from the patient. This choice; possibly 
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recommended by researchers, and made by clinicians draws a thin line between 
disrespecting autonomy and the principle of beneficence. This is likely a case of an ethics of 
care and specification where context is incredibly important in these situations. Another 
situation where clinicians should care about context is the difference between express and 
tacit consent. Express consent is outright making a decision and tacit consent is consent by a 
lack of objection.27 Researchers essentially demand express consent by asking patients to read 
and sign release forms and tacit consent should not be an issue for researchers. After 
reporting the secondary findings to the clinician is where tacit consent may arise when a 
patient may be unsure of reading or hearing about the report themselves.  
Informed consent with regards to human genetics research can only be achieved if 
the patient has fully understood the information disclosed by consent documents and 
clinicians. This is generally used to consent to the research or procedure that is to be done 
but the informed position may go both ways. An individual may refuse to participate in 
genetic testing based on informed refusal where they understand everything that is to be 
done but make the conscience decision to not participate. Informed refusal is not the goal of 
researchers trying to inform patients but they must respect the decision made by the patient 
based on the principle of autonomy discussed later. Informed refusal does not include the 
possibility of false beliefs or misinterpretations. An example of informed refusal with regards 
to secondary findings could include a patient who understands what genetic testing can offer 
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them but, going back to the exceptions of GINA, values disability insurance that could be 
jeopardized by the secondary findings of the test. Patients should not have to fear the 
discrimination of insurance companies or employers however there are exceptions under 
federal law that may apply in this patient’s situation. Researchers have to respect informed 
refusal in secondary findings, even if the patient’s agree to topical genetic testing like looking 
for a gene that is correlated to the patient’s phenotype. Related to informed refusal but not as 
disheartening is the possibility of patients to waiver the process of informed consent. 
Clinicians would get the waivers from the patient’s which relives the clinician of having to 
consent as the patient just consents. The patient loses the ability to be informed in this case 
but this situation is ethically and legally risky for researchers and clinicians. RG requires 
patients to provide their complete medical records and the sequencing files of the patient and 
immediate family members so relinquishing informed consent is made harder through 
release form processes.28 Adding an option for secondary findings may allow patients to just 
sign at the dotted line without understanding the benefits and risks they are taking. Release 
forms should try and mediate relinquishing informed consent because it does not benefit the 
patient to the degree that an informed decision would. Few approaches respect the autonomy 
of the patient so the best approach would include a section reminding the patient to ask 
questions they may have regarding secondary findings and include a smaller line for the 
initials of the patient. It is a right of the patients to be informed when they decide on tests 
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that affect their future and while it is a right of them to also waiver informed decision 
making, it is not recommended for optimal benefit.  
The benefits of individual patients extend to the general population when included in 
genomic data pools for research use. Data sharing in biobanks is a growing practice by 
government, research institutions and clinics with the purpose of advancing research for 
personalized and preventative medicine. The National Institutes of Health issued the 
Genomic Data Sharing Policy in 2014 which dictates that all genomic data collected for 
research funded by the NIH will be collected within a biobank. This allows scientists to use 
data that has already been collected and expedite the creation of knowledge.29 Other research 
that benefits from biobanks are studies on association between genotypes, socioeconomic 
parameters, environmental exposure and phenotypes.30 The express goal of the NIH is to 
make genomic data publicly available while also protecting the data and privacy of 
individuals. The issue of biobanks is the publicity of data and the unique genetic sequence 
that all individuals have. States now employ biobanks with newborns for identification 
purposes making total genetic non-disclosure essentially invalid. Patients may have questions 
or concerns regarding their identity and privacy if their data is included in a biobank. RG is 
not inclined to follow NIH statutes and this problem is less relevant for this institute, 
however biobanks are a concern for some patients and researchers. Debates surround 
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biobanks and how they could be used against patients or individuals but this is not relevant 
to the purpose of this thesis. I will however address the issue in brief. Biobanks are not 
something to fear for patients because it is not unlike government social identification and 
records. Non-invasive government policies already affect all individuals that are likely to be 
associated with the genetic sequencing process. With the express goal of the NIH being the 
privacy of the genetic data collected for some research, there is little concern for the abuse of 
genetic information.  
Research institutions need to make these documents readable and available to 
patient’s; providing the options for patients to act autonomously and voluntarily while also 
acting ethically and beneficently. The FDA’s regulations on informed consent require that 
information presented to the patient should be in language understandable to the patient. No 
language should be used where the patient must waive or appear to waive any legal rights or 
release the institution from liability in the case of negligence.31 The language of 
release/consent forms are very important for all parties involved. The forms must be concise 
yet informative and readable which is sometimes difficult when discussing genetics and 
medical jargon. While a majority of researchers, research participants and patients desire to 
report secondary findings, studies suggest that research participants and patients receive 
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more complex information that they can reasonably assimilate and use in decision making.32 
The assumption made is based on the reasonable person standard which assumes that 
information is disclosed to a hypothetical rational and reasonable person. This is a best case 
scenario when informing patients and their families but this cannot be true in all cases. 
Sometimes the patient is a non-autonomous individual like a child whose parents or 
surrogates do not have the ability to comprehend the ramifications of analysis and secondary 
findings and may not be able to read consent forms. Information needs to be tailored to that 
individuals needs which is difficult to achieve when institutions like RG are separated from 
the patient. The clinician or genetic counselor has the best ability to tailor the information to 
the patient so it is recommended that the patient consult their care provider before making 
decisions. For the part of the researchers, information given to the patient should be in 
language that is understandable to the general population. Simon et al. analyzed the average 
grade level readability of language found in reports and forms given to patients and found 
that the average grade level found in analysis given to patients ranged from 9-12.33 This is a 
fair range for most people with a high school diploma but not everyone who may be a 
patient or decision maker has that accomplished. The best thing for research institutions to 
do would be making their forms as understandable as possible which can be a difficult feat to 
achieve. Because of the difficulty of the language and topic, it would be best if the patient 
was to consult their clinician or genetic counselor before making a decision.   
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Clinicians will often be the ones to consult the patients and disclose the information 
provided by the research institutions but there will need to be a combined effort between 
the clinicians and researchers in obtaining autonomous consent from patients. The method 
for contact and consent of patients for the research institution is in-depth consent forms. 
These medical forms are the basis for communication between researchers and patients. The 
problem that patients may experience is processing the amount of information given to them 
and how to respond to the data. The medical release form for RG that relinquishes the 
genetic and medical information to researchers is sent directly to the patient who then sends 
the form back to the institute. There is no contact between patients and medical 
professionals like clinicians or genetic counselors who could help inform patients about what 
they are giving to the institute and what they can expect in requesting secondary findings. 
Researchers have a duty to inform patients of what they will be analyzing and what the 
patient can expect but there is only so much that communication with a representative and a 
three-page form can do in informing patients. It is unreasonable to expect that a patient will 
be fully informed with this information, especially when including a secondary findings 
request section in the medical release form. If the patient has questions regarding medical 
information or secondary findings, they must contact the clinician or counselor themselves 
which is a difficult thing to expect a patient to do. In the document, I recommend that 
patient’s contact their genetic counselor if they have questions about secondary findings but 
this is only a recommendation and leaves a lot to be desired. If at all possible, it is 
recommended that the research institution go through genetic counselors or clinicians when 
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giving patients the medical release form. While sending the medical release form directly to 
patients via email expedites the process for analysis, the expectation of informed consent is 
unrealistic. If there is no change to this process it is still acceptable to send the medical 
release and secondary findings request to patients because we have given them the 
autonomous choice to be fully informed.  
 
Autonomy 
The underlying idea central to the thesis so far is the notion of autonomy. Autonomy 
is a large focus of the issue on secondary findings and the respect for patient’s autonomy and 
practicality sometimes conflict. Not surprisingly, many ethical issues arise when discussing 
autonomy and secondary findings. The patient has overriding authority on the conditions of 
their genomic data, but as is oftentimes the case with Rare Genomics patient’s, there is 
surrogate decision maker because the patient is unfit to make their own autonomous 
decisions. These patients could be infants or children or unable to consent because of their 
hereditary or mental illness. The clear ethical standard for researchers is the beneficence of 
the patient. The substituted judgement standard, where a surrogate makes decisions on what 
the patient “would have made”,34 and the pure autonomy standard, where surrogates respect 
the wishes of the formerly autonomous,35 do not usually apply in these situations and tend to 
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be sub-par ethical compromises. Researchers need to adopt a best interest standard when it 
comes to secondary findings and patients.  
Autonomy is described as being a decision free of outside influence and coercion. This 
is meant as the patient making a voluntary decision to participate in the research without 
acting from another’s influence. The focus is on the decision of the patient rather than the 
outside circumstances that influence the decision like finances or personal relationships. 
Sometimes this is not the case as described above in the case of children or the mentally ill. 
There is occasionally the need for surrogate decision making which is defined as someone 
making decisions on behalf of those not capable of making informed decisions.36 Parents are 
the surrogate decision makers for children and are expected to act in the best benefit of the 
child. Parents also have the autonomous decision of whether or not to include secondary 
findings within the test reports. This is sometimes complicated when the decision to act is 
based on personal beliefs which are not always in the child’s best interest. The famous 
common example of this is the parents of Jehovah’s Witnesses who decline to give their child 
a lifesaving blood transfusion because of their beliefs. The issue connected with secondary 
findings would be the cost-benefit of getting secondary findings reported. While not as 
drastic as a blood transfusion, there is a clear benefit for the future of the child if they were 
to know things that could affect them in the years following the initial genetic testing.  
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The child itself cannot express consent but may decide that it would like access to the 
secondary findings report once they become autonomous individuals. Many issues arise 
between the future presumed autonomy of the child, the surrogate authority of the parents, 
and reporting of secondary findings. This relationship is complex in that there is the 
potential harm of labelling a child as bound to develop problems in the future (e.g. increased 
chance of certain cancers) contrasted with the benefit of knowing early enough to possibly 
plan or commit to treatment. There is also the need to protect the privacy of the child and 
their genetic information.37 The problem is further complicated by the anxiety that parents 
may experience at having transferred diseases to their child or discovering non-paternity 
through analysis. Solutions to these problems are incredibly contextual and involve 
researchers, patients, surrogates and clinicians alike. Should the parents deny reporting of 
secondary findings via informed refusal, then that leaves the child at a loss of information 
later on in life. If researchers conduct secondary finding reports on children and save them, 
the surrogate authority of the parents is challenged and the medical professionals are 
responsible for holding the information and getting it to the child when they come of age. 
The question lies with what are the child’s right to know with their own genetic 
information. The unfortunate reality is that some children will never be capable of 
autonomous decisions and in this case, the parents have the overarching authority for 
decisions. Fortunately, this is not every case and there are children that have the capability 
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to become autonomous even with hereditary disadvantages. In the interest of giving the 
child choice in the future, genetic testing institutions should allow these children to receive 
their secondary finding reports or offer to reanalyze the data when the child comes of age. 
One option is to have a preliminary list of genes to scan and save this secondary findings 
report. Another option is to offer to retest the child when they become autonomous. The 
latter option is attractive because it provides more time for genetic information technology 
and knowledge to grow, providing a more wholesome picture. Variants of unknown 
significance may be studied more in depth so researchers will know more about how 
mutations affect gene function. This assumes the institute will remain operational for a long 
period of time which may not be the case when the child becomes autonomous. Even though 
there is a chance of the institute discontinuing operations before the child becomes 
autonomous, NGS technologies are making genetic testing cheaper and cheaper.38 
Presumably genetic testing will be more affordable in the coming years making the loss of 
reanalysis by one institute near inconsequential. Research institutions like RG should offer 
reanalysis of secondary findings when the child becomes autonomous. Some companies 
already offer this for patients.39 The issue is null provided parents opt for the inclusion of 
secondary findings for the child.  
Things are further complicated when it is not the parents who are designated the 
surrogate authority or the situation is unclear. The spouse, child, family member or maybe 
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even a close friend may be the surrogate decision maker for an individual and clinicians 
should be careful when accepting decisions from surrogates. Claims about what patients 
supposedly want are inherently dubious coming from secondary parties. The relationship to 
the patient and the clinician’s opinion should be considered when considering the 
qualifications of the surrogates. Researchers are mostly separated from the patients for the 
sake of anonymity so the clinician’s viewpoint is an important factor in this case with 
decision making. Notions of the rules of surrogate authority and the rules of professional 
authority in ethics surround the issue of non-autonomous patients.40 Both of these rules serve 
to guide who should serve as a surrogate agent to the patient and when a professional has the 
right to override a patient’s decisions if they are harmful or poorly contemplated. A quality 
of life standard is usually adopted where a surrogate makes the decisions in the patient’s and 
the family’s best interest. The issue here is that the surrogacy dynamic sometimes clashes 
with the professional opinion of clinicians or researchers. Researcher’s concerned over the 
decision made about the patient have little effect on the decision making regarding 
secondary findings. Even given multiple important findings that could affect the patient 
adversely, if the patient or surrogate agent declines including these findings through 
informed refusal, the researcher must respect the autonomy of these patients. Something a 
researcher may do is look for these secondary findings save them in case the patient decides 
to revisit the findings later or give them to the patient’s clinician to file away should they 
have a moral and ethical defense for doing so.  
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Patients need only a substantial understanding of affairs for the decision to be 
considered autonomous. A patient may act autonomously without exercising their right to 
information. A patient who signs the form authorizing secondary findings without reading 
the information provided is still qualified to act autonomously but chooses not to do so.41 
Examples like this bring up the debate of what autonomous people want vs. what they 
should want. For secondary findings, it is easy to assume that the logical patient would want 
as much information available to them so they can make the best autonomous choice. This is 
not always the case for example, patients may fear learning of other problems they may 
experience or may not care to learn any more than they have to. People are attracted to 
medicinal clinics because they provide professionals qualified to deal with diagnoses and 
disease. People are directed to institutes like RGI because these places offer more information 
analyzed by qualified individuals that benefit the patients. Clearly patients wish to be 
informed but generally agree to have the medical professionals guide them and make 
decisions.42 With this in mind, some patients may ask clinicians to make the decision for 
them believing that they are more informed and will make the best decision on their behalf. 
Autonomy is a right of the patient and it should not be confused as a duty of the patient for 
this puts undue pressure onto patients. Researchers cannot force people to make decisions 
they do not want to make. Making patients delegate on every issue when they have made it 
clear they wish to delegate that responsibility elsewhere is a clear violation of autonomy. 
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While the medical professionals should not push the patients to decide everything, in a 
standard clinic there is a clear risk of clinician bias towards certain methods of operation that 
may not actually be in the best interest of the patient. In the case of genetics testing and in 
order to provide the most information possible to the patient for future use, if a clinician or 
researcher is given the choice for the autonomous patient then they should have the 
secondary findings reported and stored with the clinician for the patient’s benefit. Having 
the information accessible to the patient who may be unsure of how to address secondary 
findings at the time or in the future gives the patient the most options to work with. The act 
of patients passing on their autonomous decisions to those they view as more qualified 
should clearly benefit them and having options gives the patient considerable freedom with 
their genetic information. This is in line with the notion of mutual decision making between 
the patient and the qualified professional discussed previously. The medical professional has 
too much power over information and the patient may not know what they are signing up 
for. Researchers and clinicians should advocate for reporting secondary findings to patients 
but should remain conscious of the patient’s overarching autonomy.  
The approach that is described to benefit the patient with regards to autonomy is 
choice. Giving options to patients is the best approach to an informed consent policy 
regarding human genetics research and secondary findings. In a study that analyzed the 
many informed consent forms around the western world given to patients, it found that 
around one third of the documents provided a clause for whom researchers were able to give 
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information to regarding the individual research results (IRR) and incidental findings (IF, 
also known as secondary findings). The options given were the patient’s doctor, a spouse or 
family member and other.43 Documents like this tackle two problems by establishing 
autonomy of the patient through choice and giving solutions to where secondary findings 
may be sent after analysis. Rather than asking the patient to give a binary answer of whether 
they would like to receive secondary findings, they are given the chance to evaluate where 
they would like the information retained before testing. Information overload for patients is 
a challenge that researchers face when obtaining consent. The diversity of patient’s 
knowledge of genetics and biology may lead to issues where an individual does not have the 
capability to fully understand what is being asked of them and how to interpret the data. 
Oftentimes the mode of presenting risks or consequences to patients has an outcome on their 
decisions.44 Rephrasing certain terms like “secondary findings” to things such as “other 
findings” may have a large impact on if a patient will consent to the research and if they 
would be willing to receive secondary findings. Similarly, expressing probability in numeric 
and non-numeric means and the use of analogies also helps the patient as well as opening up 
the possibility of more people having a better understanding secondary findings. Using 
simplified terms to get across the importance of secondary findings and the research itself is 
invaluable in consent forms sent to patients and their families. An example of this would be 
providing metaphor examples for patients to better understand genetics jargon. Providing 
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examples of how secondary findings have affected people and diagnoses may also provide the 
patients with a sense of how genetics testing and these findings are important.  
 
What Should Be Included in a Secondary Findings Report? 
Informed consent and autonomy are given ethical values that benefit both the 
patients and researchers. Within the chapters on informed consent and autonomy, vague 
mentioning of certain aspects of secondary findings reports occurred. An example would the 
section on how to dissuade patients from relinquishing informed consent. The purpose of 
this chapter is to summarize what and how information should be included within secondary 
findings reports with the focus on the inner workings of the Rare Genomics Institute.  
In order to discuss the method of presenting secondary findings to patients, RG 
operations need to be explained. The Rare Genomics Institute operates as a non-profit 
organization designed to help diagnose and research rare diseases around the world. The goal 
is to help patients with finding personalized research projects and diagnoses.45 The patient or 
the patient’s family contacts RG usually with the guidance of a physician and are then sent 
an application and medical release form. Patients are assigned a Patient Advocate who is the 
contact between the patient and RG and helps guide them through the exome sequencing 
and analysis process. RG then connects the patient with a clinical geneticist who then 
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determines the eligibility of sequencing and what tests would be beneficial to have 
beforehand. After being approved for testing the results take around 2-6 months to be report 
back with between 1/3 and ¼ of patients receiving new diagnoses. After initial testing, 
patients who desire further analysis of the raw data are dealt with by the RG Science 2.0 
team. The most desired outcome is that a gene is identified that is likely causative of the 
patient’s problems and RG recommends possible treatment or research options for the 
patient to pursue. Some patients are reluctant to commit to testing for various reasons 
including monetary ones. RG helps families crowdfund their sequencing by the 
recommended clinical geneticists through posting the story of the patient on their website.46 
The process of analysis begins after the director of RG’s Science 2.0 team accepts the case. 
The cases are passed to volunteer analysts who complete a report which is then edited by the 
director of the team. A case will only be submitted if it has been reviewed by RG’s global 
network of experts, the analyst and a Community Manager. Once this has been completed, 
the director of the Science 2.0 team edits the final report and sends it to the family.  
The argument of this thesis is that a secondary findings report should be included 
within the final report given to the patient. Currently RG does not deal with secondary 
findings so the list of genes on the report are only the ones that pertain to the phenotype and 
medical history of the patient. In order to sign up for genetic testing and analysis of results 
through RG, patients must fill out a three-page medical release form which asks for the 
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complete medical records of the patient and the genetic sequencing files of the patient and 
immediate family members. Bolded are the words; TYPE OF INFORMATION REQUESTED 
and below the two requested items is a section on patient rights and cancellation notices. The 
patient’s rights state that the signatory has the right to revoke or cancel the medical release 
authorization at any time in writing. The cancellation notice section relieves RG of the 
liability of information being released before the receipt of the written notice for 
cancellation.  
 
TYPE OF INFORMATION REQUESTED 
Complete medical records of patient 
Genetic sequencing files of patient and immediate family members 
 
PATIENT RIGHTS 
You have the right to revoke or cancel this authorization, in writing, at any time 
CANCELLATION NOTICE 
Rare Genomics Institute will not be held responsible for any release of medical information 
accomplished before receipt of a written notice cancellation. Revocation takes place from the 
date of receipt of written request.  
 
Figure 2: Section of the Rare Genomics Institute’s medical form given for 
visualization.47 
This small section of the medical release form is an optimal place for the secondary findings 
request and subsequent relevant information. It is placed just below what is being requested 
                                                          
47 Institute, Rare Genomics. “Authorization for The Release of Medical Information,” n.d. 
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via the medical release form and just above the instructions for release cancellation. The 
patient will see both the summary of what they will receive, their rights and what course of 
action they may take should they change their mind about genetic testing. The wording for a 
section designed to ask whether a patient wants secondary findings to be reported should be 
similar to the legal language of the medical release form. As discussed on pages 25, it should 
contain two signatory sections so that a patient will be more encouraged to be informed and 
not relinquish their right to informed consent. The section itself should have a request for 
whether the patient would want a secondary findings report to be included with the results 
of the Science 2.0 team’s analysis, as well as instructions for who is to receive the report if 
not just the patient. Included under the question with a yes or no checkmark should be a 
brief definition of secondary findings, a suggestion to talk to a trusted clinician, and the legal 
rights of a patient.  
This section should absolutely be separate from the medical release request 
information because it is more important that the patient understand that secondary findings 
are optional which is why it should include a separate signatory section. Similarly, a short 
blurb on the Genetic Information Non-Discrimination Act is included in the section on 
“Patient’s Rights” as discussed in the Informed Consent chapter. An example of what the 
medical release form should include is written below.  
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INFORMATION TO BE RELEASED BY  
 
 
 
INFORMATION TO BE RELEASED TO 
 
Organization: Rare Genomic Institute 
Address: 2657 Annapolis Road, Suite G #105, Hanover, MD 21076 
Contact name: Romina Ortiz 
Contact Email: romina.ortiz@raregenomics.org 
 
TYPE OF INFORMATION REQUESTED 
Complete medical records of patient 
Genetic sequencing files of patient and immediate family members 
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*Newly Added Section 
Secondary findings are defined as being medical information that is discovered 
unintentionally and is unrelated to the condition being tested. These would be diseases that 
the patient is susceptible to develop in the future. We recommend you discuss the 
implications of these findings with your doctor before agreeing to the secondary findings.  
For more information on secondary findings, please visit this website: 
(http://bioethics.gov/sites/default/files/Clinician%20Primer%20-%20FINAL.pdf) 
Would you like to include a secondary findings report in addition to the analysis report for 
the condition being tested? 
 __ Yes    __ No 
If you would like to delegate who should receive these findings, please contact your Patient 
Advocate. 
 
PATIENT RIGHTS 
You have the right to revoke or cancel this authorization, in writing, at any time 
*Newly Added Section 
You are protected under federal law by the Genetic Discrimination Non-Discrimination Act 
to not be discriminated against because of your genetic data by employment or health 
insurance companies. This law does not apply to employers with fewer than 15 employees 
nor disability or life insurance policies. Local and State laws vary on added protections; we 
recommend you discuss the legal implications of genetic testing with your clinician or 
genetic counselor before submitting this form. 
CANCELLATION NOTICE 
Rare Genomics Institute will not be held responsible for any release of medical information 
accomplished before receipt of a written notice cancellation. Revocation takes place from the 
date of receipt of written request.  
I understand that the information I give is my own submission of medical tests, treatments 
and results pertaining to myself, my child, and immediate family.  
I hereby consent to the release of the specified information I am giving through the medical-
records sharing website Patients Know Best and allow you to use it only for research 
purposes including sharing de-identified information with external experts and 
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phenotype/genotype databases. I understand that such information cannot be released 
without my informed consent. I acknowledge I have fully reviewed and understand the 
contents of this authorization form. My signature below indicates that I hereby agree to and 
authorize the release of patient health information to Rare Genomics Institute. 
 
Instructions for Canceling a Request 
You must provide a written request to romina.ortiz@raregenomics.org for 
revocation/cancellation of the original record release.  
We need to have your complete name, date-of-birth, telephone number (home/work) and 
the name of the person/agency that you authorized to receive the medical information. 
After receipt of the notice, email confirmation will acknowledge your withdrawal of 
authorization.  
If you have any questions concerning the cancellation process, email. 
romina.ortiz@raregenomics.org 
 
 
 
 
There is room for volunteer analysts to add on a secondary findings report from the 
test results onto the final report. The time it takes to check a list of around 65 genes would 
only be a small part of total time taken for analysis. Providing filters for genes targeted to be 
reviewed by analysts are already a part of many databases like Omicia Opal. Adding filters 
for secondary findings reports streamlines the process and allows analysts to make the call 
over whether a mutation is significant enough to report or not. As discussed earlier, there are 
Figure 3: Recommendation for the secondary findings 
addition to the medical release form. 
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concerns over mistakes about the significance of the gene. In the case of these genes, they 
tend to be monogenic disorders that have been studied extensively and have been shown to 
be pathogenic. With the use of Clinvar, COSMIC and Omicia Opal, these genes have been 
determined to be problematic for individuals; without necessarily expressing a clear 
phenotype of the disease. Omicia has an indicator of the likelihood of deleteriousness of a 
mutation which is a good start to analysis. The genetic information loaded onto Omicia is 
analyzed by the database which shows indicators of deleteriousness as well as what kind of 
mutation occurred. The template genome comes from the 1000 Genome Project and Omicia 
compares the subject’s genome to this collection to determine what has been mutated. 
RG’s genetic analysis is not supposed to be the end all with genetic sequencing. One 
issue that should be made clear within the language of consent forms is that these secondary 
findings are not a final diagnosis. Often mutations within certain genes just increase the 
likelihood of developing the disease that has been associated with that gene. RG’s analysis of 
genetic data is not entirely comprehensive for there are other problems that can be identified 
from the genome that RG does not look for. There is a lot of information to be analyzed from 
whole exome sequencing and we do not currently have the capability of determining 
everything that is possibly disease causing. Included in this thesis are carrier status genes, 
primarily X-linked, that are mutated but do not affect the carrier of the mutated gene. The 
reason for reporting these genes is to inform the patient or immediate family members that 
they have a possibility of passing on this mutated gene to future offspring which could be 
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deleterious. An example of this is Fabry’s disease which is a recessive lysosomal storage 
disease that is found on the X chromosome and affects all males with the mutation as well as 
affects homozygous and some heterozygous females. Informing patients that they are a 
carrier for this disease can affect the future decisions of said patient and may help diagnose 
other immediate family members with the same mutation. There are far too many of these 
kinds of diseases for one secondary findings report to cover. RGs secondary findings report 
would cover some of the most important diseases to date with room for improvement in the 
future. For a complete analysis of what parents could pass on to their offspring, they will 
need to approach another genetic analysis opportunity. RG is devoted to figuring out the 
cause of a patient’s suffering and preventing future cases of the disease through 
individualized care and they cannot possibly be the end-all for any genetic disease that a 
patient may have.  
 
Content of Secondary Findings Report 
 The meat of any secondary findings report are the genes that are found to be 
significantly mutated and likely deleterious. The following genes come from both the 
American College of Medical Genetics and Genomics list of recommended genes and 
research of monogenic disorders. This section goes through the ACMG list in alphabetical 
order by gene. The end will be genes that I recommend be added to both this list and to 
secondary findings reports which are listed as new recommendations. The list is kept short 
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because RG testing is not an end-all of genetic testing and there is more to be learned about 
certain genes which may be determined to be deleterious.  
 The table is organized alphabetically by gene and includes the disease that the gene is 
associated with, the inheritance pattern, disease type and recommender. The disease is 
hopefully explained a little bit by the disease type which is just a basic category or 
consequence of having the deleterious gene. The legend shows the acronyms for the 
inheritance patterns found on the list. One may refer back to the chapter An Introduction to 
Genetic Analysis for more information and a refresher on some of the terms used in the 
upcoming section. The table is designed to reflect the inheritance of the disease that is 
included on the list with subsequent inheritance (separated by a hyphen) that are in the 
same row represent the inheritance of other diseases that the gene is associated with.  
 
Legend 
AD = Autosomal Dominant XL = X-Linked 
AR = Autosomal Recessive XLR = X-Linked Recessive 
Smu = Somatic Mutation XLD = X-Linked Recessive 
Mu = Multifactorial ? = Unknown Inheritance  
 
Gene Disease Inheritance Disease Type Recommender  
ACTA2 
Aortic aneurysm, familial 
thoracic 6  
AD Heart Disease ACMG listed 
ACTC1 
Familial hypertrophic 
cardiomyopathy 11 
AD Heart Disease ACMG listed 
APC 
Adenomatous polyposis 
coli  
AD 
Cancer 
Susceptibility  
ACMG listed 
APOB 
Familial 
hypercholesterolemia 
AD - AR? 
Elevated 
Cholesterol 
ACMG listed 
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Gene Disease Inheritance Disease Type Recommender  
ATRX 
Alpha-Thalassemia/Mental 
Retardation Syndrome 
XLD 
Mental 
Retardation - 
Carrier status 
New Rec. 
BRCA1 
Breast-ovarian cancer, 
familial 1 
AD 
Cancer 
Susceptibility  
ACMG listed 
BRCA2 
Breast-ovarian cancer, 
familial 2 
AD 
Cancer 
Susceptibility  
ACMG listed 
CACNA1S Malignant hyperthermia AD - ? 
Skeletal Muscle 
Disorder - 
Volatility to 
Anesthesia 
ACMG listed 
CFTR Cystic Fibrosis AR Carrier status New Rec. 
COL3A1 
Ehlers-Danlos syndrome, 
type 4 
AD 
Proneness to 
Rupture of 
Arteries 
ACMG listed 
DMD 
Duchenne Muscular 
Dystrophy  
XLR 
Progressive 
Proximal 
muscular 
dystrophy 
New Rec. 
DMD 
Becker Muscular 
Dystrophy  
XLR 
Progressive 
Proximal 
muscular 
dystrophy less 
severe 
New Rec. 
DSC2 
Arrhythmogenic right 
ventricular 
cardiomyopathy, type 11 
AD Heart Disease ACMG listed 
DSG2 
Arrhythmogenic right 
ventricular 
cardiomyopathy, type 10 
AD Heart Disease ACMG listed 
DSP 
Arrhythmogenic right 
ventricular 
cardiomyopathy, type 8 
AD Heart Disease ACMG listed 
FBN1 Marfan's syndrome AD 
Connective 
Tissue Disease - 
Dominant 
Negative 
ACMG listed 
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Gene Disease Inheritance Disease Type Recommender  
FMR1 Fragile X syndrome XLD 
Mental 
Retardation - 
Carrier status 
New Rec. 
GLA Fabry's disease XL 
Heart Disease 
and Renal 
Failure 
ACMG listed 
HTT Huntington’s Disease AD 
Progressive 
Neuronal 
Degeneration 
New Rec.  
IDS 
Mucopolysaccharidosis 
type II 
XLR 
Progressive 
Degeneration 
New Rec.  
IKBKG Incontinentia Pigmenti XLD Carrier status New Rec. 
KCNH2 Long QT syndrome 2 AD Heart Disease ACMG listed 
KCNQ1 Long QT syndrome 1 AD - AR? Heart Disease ACMG listed 
KRAS Leukemia, acute myeloid AD 
Cancer 
Susceptibility  
New Rec. 
LDLR 
Familial 
hypercholesterolemia 
AD 
Elevated 
Cholesterol 
ACMG listed 
LMNA 
Dilated cardiomyopathy 
1A 
AD - AR? Heart Disease ACMG listed 
MEN1 
Multiple endocrine 
neoplasia, type 1  
AD 
Cancer 
Susceptibility  
ACMG listed 
MLH1 Lynch syndrome AD 
Cancer 
Susceptibility  
ACMG listed 
MSH2 Lynch syndrome AD - AR? 
Cancer 
Susceptibility  
ACMG listed 
MSH6 Lynch syndrome AD 
Cancer 
Susceptibility  
ACMG listed 
MUTYH MYH-associated polyposis SMu 
Cancer 
Susceptibility  
ACMG listed 
MUTYH Pilomatrixoma SMu 
Cancer 
Susceptibility  
ACMG listed 
MYBPC3 
Dilated cardiomyopathy 
1A 
AD Heart Disease ACMG listed 
MYBPC3 
Familial hypertrophic 
cardiomyopathy 4 
AD Heart Disease ACMG listed 
MYH11 
Aortic aneurysm, familial 
thoracic 4  
AD Heart Disease ACMG listed 
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Gene Disease Inheritance Disease Type Recommender  
MYH7 
Familial hypertrophic 
cardiomyopathy 1 
AD Heart Disease ACMG listed 
MYL2 
Familial hypertrophic 
cardiomyopathy 10 
? Heart Disease ACMG listed 
MYL3 
Familial hypertrophic 
cardiomyopathy 8 
AD Heart Disease ACMG listed 
MYLK 
Aortic aneurysm, familial 
thoracic 7  
AD Heart Disease ACMG listed 
NDP Norrie Disease XLR 
Degenerative 
Blindness and 
Mental 
Capacities 
New Rec. 
NF2 Neurofibromatosis, type 2 AD 
Cancer 
Susceptibility  
ACMG listed 
OTC 
Ornithine 
transcarbamylase 
deficiency 
XLR 
Metabolic 
Disorder 
New Rec. 
PCSK9 
Hypercholesterolemia, 
autosomal dominant, 3 
AD 
Elevated 
Cholesterol 
ACMG listed 
PKP2 
Arrhythmogenic right 
ventricular 
cardiomyopathy, type 9 
AD Heart Disease ACMG listed 
PMS2 Lynch syndrome ? 
Cancer 
Susceptibility  
ACMG listed 
PRKAG2 
Familial hypertrophic 
cardiomyopathy 6 
AD Heart Disease ACMG listed 
PRNP 
Gerstmann-Straussler 
Disease 
AD 
Prion Caused 
Progressive 
Degeneration 
New Rec. 
PTEN 
PTEN hamartoma tumor 
syndrome 
AD - AR? 
Cancer 
Susceptibility  
ACMG listed 
RB1 Retinoblastoma SMu - AD? 
Occular 
Degeneration 
ACMG listed 
RET 
Familial medullary thyroid 
carcinoma 
AD 
Cancer 
Susceptibility  
ACMG listed 
RET 
Multiple endocrine 
neoplasia, type 2a 
AD 
Cancer 
Susceptibility  
ACMG listed 
RET 
Multiple endocrine 
neoplasia, type 2b 
AD 
Cancer 
Susceptibility  
ACMG listed 
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Gene Disease Inheritance Disease Type Recommender  
RYR1 Malignant hyperthermia AD -  AR? 
Skeletal Muscle 
Disorder - 
Volitility to 
Anestesia 
ACMG listed 
RYR2 
Catecholaminergic 
polymorphic ventricular 
tachycardia 
AD Heart Disease ACMG listed 
SCN5A Brugada syndrome 1 AD Heart Disease ACMG listed 
SCN5A Long QT syndrome 3 AD Heart Disease ACMG listed 
SDHAF2 Paragangliomas 2 AD 
Cancer 
Susceptibility  
ACMG listed 
SDHB Paragangliomas 4 AD - ? 
Cancer 
Susceptibility  
ACMG listed 
SDHC Paragangliomas 3 AD - ? 
Cancer 
Susceptibility  
ACMG listed 
SDHD Paragangliomas 1 AD - AR? 
Cancer 
Susceptibility  
ACMG listed 
SMAD3 
Loeys-Dietz syndrome 
type 3 
AD Heart Disease ACMG listed 
SMAX1 
Spinal and bulbar 
muscular atrophy 
XLR 
Muscular 
Degeneration 
New Rec. 
STK11 Peutz-Jeghers syndrome 
AD - SMu, 
Mu? 
Cancer 
Susceptibility  
ACMG listed 
TGFBR1 
Loeys-Dietz syndrome 
type 1A 
AD Heart Disease ACMG listed 
TGFBR1 
Loeys-Dietz syndrome 
type 2A 
AD Heart Disease ACMG listed 
TGFBR1 Marfan's syndrome AD 
Connective 
Tissue Disease  
ACMG listed 
TGFBR2 
Loeys-Dietz syndrome 
type 1B 
AD Heart Disease ACMG listed 
TGFBR2 
Loeys-Dietz syndrome 
type 2B 
AD Heart Disease ACMG listed 
TMEM43 
Arrhythmogenic right 
ventricular 
cardiomyopathy, type 5 
AD Heart Disease ACMG listed 
TNNI3 
Familial hypertrophic 
cardiomyopathy 7 
AD - AR? Heart Disease ACMG listed 
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Gene Disease Inheritance Disease Type Recommender  
TNNT2 
Left ventricular 
noncompaction 6 
AD Heart Disease ACMG listed 
TP53 Li-Fraumeni syndrome 1 
AD - AR, 
SMu? 
Cancer 
Susceptibility  
ACMG listed 
TPM1 
Familial hypertrophic 
cardiomyopathy 3 
AD Heart Disease ACMG listed 
TSC1 Tuberous sclerosis 1 AD - ? 
Cancer 
Susceptibility  
ACMG listed 
TSC2 Tuberous sclerosis 2 AD 
Cancer 
Susceptibility  
ACMG listed 
VHL 
Von Hippel-Lindau 
syndrome 
AD - AR? 
Cancer 
Susceptibility  
ACMG listed 
WAS 
Wiskott-Aldrich 
Syndrome 
XLR 
Autoimmune 
Deficiency - 
Carrier status 
New Rec. 
WT1 Wilms' tumor 
SMu - AD, 
AR? 
Cancer 
Susceptibility  
ACMG listed 
 
 Similar characteristics found on this list are disease type and mode of inheritance. A 
lot of the genes recommended are associated with heart disease or cancer susceptibility. This 
pattern is representative of the severity of diseases that these genes cause. Heart diseases and 
cancer are highly lethal even with today’s modern medical practices. One common trait that 
almost all of these genes share is that they do not display symptoms until later in life. 
Diseases like Familial hypertrophic cardiomyopathy and Familial medullary thyroid 
carcinoma do not present symptoms until 40 or 50 years into life, and one of these symptoms 
is sudden death. All of these genes are included because the patient may not know that they 
are susceptible to these diseases at the time of genetic testing. Many of these diseases show 
autosomal dominant inheritance meaning people have a roughly 50% chance of obtaining 
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the mutated and problem causing gene from their affected parents. The severity of the 
disease and the mode of inheritance are also primary factors in what is included on this list, 
for both the ACMG recommended genes and the new recommendations. Some of the genes 
listed were included primarily for carrier status where an affected individual does not display 
symptoms of the disease but have a high likelihood of passing a severe disease to offspring. 
The reasoning behind including these genes is very similar but the genes themselves have 
different effects on the body. Each gene listed can cause this disease if mutated by itself. One 
example of a disease that has a multitude of genes associated with it is Arrhythmogenic right 
ventricular cardiomyopathy (ARVC). This disease is an example of a severe heart disease and 
is not unlike the other heart conditions that have been known to cause sudden death.   
 Arrhythmogenic right ventricular cardiomyopathy is a disease where fatty tissues 
replace cardiomyocytes in the right or both ventricles of the heart and symptoms include 
cardiac irregularities, syncope and sudden death. Multiple genes are correlated to this disease 
leading to different types or variants that each gene is causative of. The five known genes 
responsible for ARVC are TMEM43, DSP, PKP2, DSG2, DSC2. The TMEM43 gene is 
responsible for ARVC type 5 and is a response element for an adipogenic transcription factor. 
A loss of function in this gene is suggestive of how fibrofatty replacement occurs within the 
heart.48 DSP causes ARVC type 8 and has been found connected to other diseases like 
Kertoasis Palmoplantaris Striata II, Wolly Hair, Lethal Acantholytic Epidermolysis Bullosa 
                                                          
48 Bengtsson, Luiza, and Henning Otto. “LUMA Interacts with Emerin and Influences Its Distribution at the Inner 
Nuclear Membrane.” Journal of Cell Science 4, no. 124 (2007): 538–46. doi:10.1242/jcs.019281. 
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and Keratoderma. The DSP protein is a part of the desmosome intermediate filament 
complex which connects cells together and is a part of the insoluble core. Homozygous and 
heterozygous mutations in this gene are known to cause the diseases listed up above. Some 
phenotypes of this disease involve rapid degeneration to heart failure at the age of four. 
Many different mutations, both homozygous and heterozygous, have been identified as 
causative for severe diseases in the DSP gene and making this an important gene to report to 
patients.49 PKP2 is also associated with the desmosome complex as well as participates in 
linking cadherins to intermediate filaments. Mutations in this gene cause ARVC type 9 and 
patients exhibiting PKP2 mutations show arrhythmia earlier non-PKP2 mutations. PKP2 
mutation inheritance is autosomal dominant so one mutated allele has the power to create 
the disease in an individual.50 The fourth gene is DSG2, which is associated with ARVC type 
10 and is also a part of the desmosome. ARVC caused from this gene is autosomal dominant 
and dysfunctional DSG2 proteins have been found from many different types of mutations 
within the gene. 51 The last gene is DSC2 which is another gene important to the desmosome 
complex and causes ARCV type 11. Studies on zebrafish embryos of DSC2 knockouts showed 
DSC2 was crucial in developing normal cardiac tissues and lead to myocardial contractility 
defects. Similar to PKP2, this gene has been implicated in other hereditary diseases like 
                                                          
49 O’Neill, Marla J. F. “DESMOPLAKIN; DSP.” OMIM, 2015. http://www.omim.org/entry/125647?search=DSP 
&highlight=dsp. 
50 O’Neill, Marla J. F., and Patti M. Sherman. “PLAKOPHILIN 2; PKP2.” OMIM, 2008. 
http://www.omim.org/entry/602861?search=PKP2&highlight=pkp2. 
51 McKusick, Victor A., and Paul J. Converse. “DESMOGLEIN 2; DSG2.” OMIM, 2011. 
http://www.omim.org/entry/125671?search=DSG2&highlight=dsg2. 
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palmoplantar keratoderma and woolly hair.52 All of these genes are autosomal dominant and 
are causative of a severe disease that causes sudden death in individuals. The severity and 
ease of obtaining the disease are indicative of why these five genes should be included in 
secondary findings reports.  
MYH11, MYLK and ACTA2 are another set of genes that are associated with heart 
disease. These genes are associated with familial thoracic aortic aneurysm with dissection 
(TAAD) 4, 7, and 6 respectively. This disease is associated with the dilation of the aorta and 
has been known to suddenly rupture making this a serious cardiac condition. Symptoms can 
show up anywhere from childhood to late adulthood. MYH11 encodes for the smooth 
muscle myosin heavy chain and is found all throughout the body. The MYH11 gene is 
connected to the CBFB gene which encodes for the CBF-Beta protein. Mutations in this 
region of MYH11 and the CBFB gene are associated with acute myeloid leukemia, making 
mutations in the MYH11 significant53 and enough to report as a secondary finding. Another 
factor in the significance of this disease is that it is heterogeneous, meaning one affected 
allele in the individual is enough to cause the disease.  ACTA2 encodes for an alpha actin 
found in skeletal muscle and constitute a major part of the contractile apparatus54. Both 
MYH11 and ACTA2 are a part of the smooth muscle cell contractile unit affecting the aorta, 
                                                          
52 McKusick, Victor A., and Marla J. F. O’Neill. “DESMOCOLLIN 2; DSC2.” OMIM, 2012. 
http://www.omim.org/entry/125645?search=DSC2&highlight=dsc2. 
53 Liu, P. Paul, Lucio H. Castilla, Lisa Garrett, Neeraj Adya, Donald Orlic, Amalia Dutra, Stacie Anderson, Jennie 
Owens, Michael Eckhaus, and David Bodine. “The Fusion Gene Cbfb-MYH11 Blocks Myeloid 
Differentiation and Predisposes Mice to Acute Myelomonocytic Leukaemia.” Nature Genetics 23, no. 2 
(October 1, 1999): 144–46. doi:10.1038/13776. 
54 “ACTA2 Actin, Alpha 2, Smooth Muscle, Aorta.” NCBI. Accessed March 11, 2016. 
http://www.ncbi.nlm.nih.gov/gtr/genes/59/. 
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however one study suggested that mutations in either or both of these genes accounted for 
only around 20% of all familial TAAD diagnoses. Guo et al. (2007) suggested that other 
unknown mutations are significant factors in whether an individual develops familial 
TAAD.55 The MYLK gene encodes for myosin light chain kinase which is a key enzyme in 
muscle contraction. This gene has also been associated with cases of familial TAAD where 
Wang et al. (2010) identified two heterozygous variants that seemed to be causative.56 The 
MYLK and MYH11 genes have been known to be heterozygous and correlated with familial 
thoracic aortic aneurysms meaning one copy of these mutated genes are causative. The 
disease can cause sudden death making these mutations possible significant to a patient and 
should be reported. While studies suggest that they account for a low amount familial TAAD 
cases, these are still significant enough to inform patients about their chances of developing a 
cardiovascular disease. The ignorance of other causes of this disease makes reporting these 
genes only likely significant, however beforehand knowledge of susceptibility to familial 
TAAD is reason enough to be included in a report. The ACTA2 gene is connected with the 
MYH11 encoded protein so it should be reported along with the other two.   
  One of the most discussed sets of genes that affect a large number of people around 
the world are the BRCA1 and BRCA2 genes. These genes are known as tumor suppressors 
and play roles in transcription, DNA repair and recombination. The BRCA1 gene is a part of 
                                                          
55 Guo, Dong-Chuan, Hariyadarshi Pannu, Van Tran-Fadulu, Christina L Papke, Robert K Yu, Nili Avidan, Scott 
Bourgeois, et al. “Mutations in Smooth Muscle α-Actin (ACTA2) Lead to Thoracic Aortic Aneurysms and 
Dissections.” Nature Genetics 39, no. 12 (December 11, 2007): 1488–93. doi:10.1038/ng.2007.6. 
56 Wang, Li, Dong-Chuan Guo, Jiumei Cao, Limin Gong, Kristine E Kamm, Ellen Regalado, Li Li, et al. “Mutations 
in Myosin Light Chain Kinase Cause Familial Aortic Dissections.” The American Journal of Human Genetics 
87 (2010): 701–7. doi:10.1016/j.ajhg.2010.10.006. 
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a genome surveillance complex and is responsible for around 40% of breast cancers and a 
larger percentage of ovarian cancers.  The TP53 tumor suppressor gene works with the 
BRCA1 gene and mutations in both of these are found in 70%-80% of BRCA1 mutated breast 
cancers.57 Having non-functional BRCA1 gene has also been implicated in pancreatic 
cancers. The BRCA2 gene is similar and plays a role in completion of cell division and DNA 
repair. With breast cancer, a mutated BRCA2 gene also shows connections with early onset 
prostate cancer in males.58 Both genes show autosomal dominant inheritance and both have 
high rates of cancer making them important to report to patients. These are only a few of the 
diseases on the ACMG’s list of secondary findings but they are inclusive of the general 
attitude that went into choosing which diseases were included.  
Proposed additions to the ACMG list  
Rationale. This small set of the listed genes is an example of the reasoning behind 
why the ACMG included these genes in their list on secondary findings. The list of experts 
that made up the list focused on the severity of the disease, when the symptoms present 
themselves and the degree of deleteriousness witnessed in known mutations. All the genes 
recommended by the ACMG are included in this list due to these factors. New 
recommendations were chosen with these criteria in mind as well as being monogenic. 
Included in this list are carrier status genes where the patient or the family has a mutated 
                                                          
57 McKusick, Victor A., and Ada Hamosh. “BREAST CANCER 1 GENE; BRCA1.” OMIM, 2016. 
http://www.omim.org/entry/113705?search=BRCA1&highlight=brca1. 
58 McKusick, Victor A., and Ada Hamosh. “BRCA2 GENE; BRCA2.” OMIM, 2016. 
http://www.omim.org/entry/600185?search=BRCA2&highlight=brca2. 
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chromosome that has a high likelihood to passing down and causing disease to future 
offspring. The reason for including carrier genes is for providing the patient with useful 
information in future planning and save offspring from debilitating diseases. If a patient 
knows that they have a 50% chance of passing a Mucopolysaccharidosis type II to a future 
male child, this information would hopefully influence their decision making. Inheritance 
patterns for these carrier status genes tend to be X-linked or autosomal dominant. Many of 
the new genes and diseases that I recommend are X-linked monogenic disorders. In studying 
monogenic disorders, a large proportion of them that were not included on the ACMG list 
were X chromosome linked. Because the mother is generally the one who passes down a 
problematic gene due to females having two X chromosomes, X-linked disorders oftentimes 
fit into the category of carrier status genes.  
MPS II (IDS) One of these carrier status genes is the is the IDS gene which, when 
mutated, causes the disease Mucopolysaccharidosis type II (also known as Hunter syndrome) 
which has been mentioned multiple times. Mucopolysaccharidosis type II is a lysomal 
storage disorder because inactivation of Iduronate 2-sulfatase. This is the enzyme which the 
IDS gene encodes for and leads to a buildup of glycosaminoglycans. These molecules disrupt 
regular functions of a cell and lead to the distinct phenotype of Hunter Syndrome.59 The 
inheritance of this disease is X-linked recessive and mostly affects males who inherit only 
one X chromosome from their mother. The life expectancy of an individual is only around 
                                                          
59 Bocchini, Carol A. “IDURONATE 2-SULFATASE; IDS.” OMIM, 2010. 
http://www.omim.org/entry/300823?search=IDS&highlight=ids. 
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10-20 years because of the progressive degeneration of function.60 This is a severe disease and 
represents only one monogenic disorder that comes from mutations in the X chromosome.  
Thalassemia and Fragile-X (ATRX, FMR1) The ATRX gene is also found on the X 
chromosome and is associated with the disease combination alpha thalassemia/mental 
retardation syndrome. The ATRX gene encodes for a protein within the helicase family and 
is believed to be associated with the regulation of gene expression and sex differentiation. 
Male patients show varying degrees of undeveloped sexual organs. Mutations that happen to 
truncate the gene and eliminate the C-terminal region tend to come with the genital 
defects.61 Many different mutations have been implicated in this disease62 which makes this 
gene important to report to patients. While this disease is more likely to affect males, it has 
been known to affect females because of X-chromosome inactivation where one X 
chromosome copy is inactivated in order to prevent overexpression. The importance of 
reporting this gene lies with the carrier status of a mutant allele. Fragile X syndrome is a very 
similar disease that is also X-linked caused by mutations in the FMR1 gene. This syndrome’s 
phenotype is moderate to high mental disabilities and patients tend to exhibit autistic 
behavior. FMR1 encodes for a protein thought to be involved in translation and is involved 
                                                          
60 “Mucopolysaccharidosis Type II.” US National Library of Medicine, National Institutes of Health, Department of 
Health & Human Services, 2016. https://ghr.nlm.nih.gov/condition/mucopolysaccharidosis-type-ii. 
61 Picketts, D J, D R Higgs, S Bachoo, D J Blake, O W Quarrell, and R J Gibbons. “ATRX Encodes a Novel 
Member of the SNF2 Family of Proteins: Mutations Point to a Common Mechanism Underlying the ATR-X 
Syndrome.” Human Molecular Genetics 5, no. 12 (1996): 1899–1907. doi:6d0165 [pii]. 
62 McKusick, Victor A., and Ada Hamosh. “ATR-X GENE; ATRX.” OMIM, 2016. 
http://www.omim.org/entry/300032?search=ATRX&highlight=atrx. 
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in neuron and hippocampus development63. Like alpha thalassemia/mental retardation 
syndrome, this disease primarily affects males because of their singular copy of the X 
chromosome but can also affect females. Also like the afore mentioned disease, it is 
important to inform patients if they are carrying a mutated copy of the gene. Reporting 
carrier status to a patient or their family may be an important piece of information if they are 
considering having a child. Mental handicaps are a serious issue for some people and the 
burden may be more than people are willing to risk. Preimplantation genetic diagnosis is 
already an established practice for in-vitro fertilization where genetic tests are run on the 
embryo which test for specific diseases or conditions.64 PGD is representative of the 
acceptance for scanning a fetus for conditions that would make life hard on the parents. This 
issue is seen in a few more new recommendations found on the list.  
Duchene and Becker Muscular Dystrophy (DMD) The DMD gene is associated with 
two related diseases, Duchenne Muscular Dystrophy and Becker Muscular Dystrophy. Both 
diseases involve progress muscle loss and resulting weakness with Becker muscular 
dystrophy being the milder form. DMD encodes for dystrophin which is believed to help 
actin maintain its bonds while under bending stress. Many different types of mutations have 
                                                          
63 Abitbol, Marc, Christian Menini, Anne-Lise Delezoide, Thomas Rhyner, Michel Vekemans, and Jacques Mallet. 
“Nucleus Basalis Magnocellularis and Hippocampus Are the Major Sites of FMR-1 Expression in the Human 
Fetal Brain.” Nature Genetics 4, no. 2 (June 1993): 147–53. doi:10.1038/ng0693-147. 
64 Hershberger, Patricia E, Catherine Schoenfeld, and Ilan Tur-Kaspa. “Unraveling Preimplantation Genetic 
Diagnosis for High-Risk Couples: Implications for Nurses at the Front Line of Care.” Nursing for Women’s 
Health 15, no. 1 (2011): 36–45. doi:10.1111/j.1751-486X.2011.01609.x. 
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been recorded to cause both of these diseases65 which may not appear until later in life. 
While this disease may not necessarily be life threatening (Duchenne muscular dystrophy 
has been known to shorten life expectancy), it has a major effect on the life of individuals. 
The loss of muscle over time affects patients negatively and it is best to inform patients of 
what they may experience in the future.  
IP and Norrie Disease (IKBKG, NDP) Incontinentia Pigmenti (IP) is an X-linked 
dominant disease that primarily affects the skin where the skin is inconsistently pigmented 
with sporadic blisters and rashes. It has also been known to influence abnormally developed 
eyes and intellectual disability. Symptoms sometimes affect newborns but progressive 
elements occur later in life and primarily affects females66. Males with the mutation do not 
tend to make it past the embryonic stage of development. The gene responsible is IKBKG 
which encodes for a NEMO-like kinase which specifically phosphorylate serine and 
threonine that are followed by a proline. Many mutations seem to be deletions within the 
gene which cause Incontinentia Pigmenti but this gene is also associated with Ectodermal 
dysplasia, hypohidrotic, with immune deficiency which proves to be a serious issue in 
affected patients. Affected males show high rates of morbidity and mortality due to recurrent 
                                                          
65 Hartz, Patricia A. “DYSTROPHIN; DMD,” 2016. 
http://www.omim.org/entry/300377?search=DMD&highlight=dmd. 
66 “Incontinentia Pigmenti.” National Institutes of Health. US National Library of Medicine, National Institutes of 
Health, Department of Health & Human Services, 2008. https://ghr.nlm.nih.gov/condition/incontinentia-
pigmenti. 
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infections67. While mutations in this gene are non-lethal for affected females, affected males 
have a high mortality rate and patients carrying the mutation should be informed that they 
are carriers. A similar disease that affects mental capabilities and blindness is Norrie disease. 
The gene associated with Norrie disease is NDP which encodes for norrin which is a cysteine 
rich protein associated with the cysteine knot growth factor family.68 Norrie Disease is X-
linked recessive and causes blindness in affected males at birth as well as can lead to 
progressive hearing loss and mental handicaps. Like IP, mutations in the NDP gene should be 
reported to patients who carry the mutation which in this case are females. Patients will 
have more information regarding whether they should have offspring that may be affected 
with these diseases so it is important to inform them of mutations in these genes. 
Ornithine Transcarbamylase Deficiency (OTC) Ornithine transcarbamylase 
deficiency is caused by mutations in the OTC gene which encodes for ornithine 
carbamoyltransferase and is involved in the urea cycle of mammals. Deficiency in this 
protein leads to increased levels of ammonia in the body which negatively affects the 
nervous system. Complications from this gene lead to an umbrella of problems for the patient 
from intellectual disability to lethargy to progressive liver damage69. Symptoms usually show 
                                                          
67 Zonana, Jonathan, Melissa E. Elder, Lynda C. Schneider, Seth J. Orlow, Celia Moss, Mahin Golabi, Stuart K. 
Shapira, et al. “A Novel X-Linked Disorder of Immune Deficiency and Hypohidrotic Ectodermal Dysplasia Is 
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up at birth but are sometimes not caught until later in life. Males are usually the ones most 
affected by this disease but females can also be affected, often through X inactivation70.  
Spinal and Bulbar Muscular Atrophy (AR) Similar to Ornithine transcarbamylase 
deficiency, Spinal and bulbar muscular atrophy primarily affects males. Symptoms of this 
disease include muscle weakness and wasting which occurs in adulthood. The AR gene is 
responsible for Spinal and bulbar muscular atrophy and encodes for the androgen receptor 
protein involved with androgen response elements. Mutations in AR have also been 
associated with Androgen insensitivity syndrome and susceptibility to prostate cancer.  
Wiskott-Aldrich syndrome (WAS) The final X-linked disorder is Wiskott-Aldrich 
syndrome that is characterized by an abnormal immune system and problems forming blood 
clots. WAS is the gene associated with this disease and is involved in Cdc42 signaling. 
Patients with Wiskott-Aldrich have a reduced number of platelets in their body and is 
caught early on in life because of ease of bleeding and bruising. They also have an increased 
chance of developing autoimmune disorders. The only known way to treat this disease is a 
bone marrow transplant71.All of these monogenic disorders have severe consequences for 
patients, usually males, that inherit mutated genes from their parents. Patients carrying these 
diseases should be informed that they have the capacity to pass debilitating or deadly 
problems on to their offspring.  
                                                          
70 Kniffen, Cassandra L., and Victor A. McKusick. “ORNITHINE CARBAMOYLTRANSFERASE; OTC,” 2006. 
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Gerstmann-Straussler disease (PRNP) Non X-linked recommendations that I made 
within this list include Gerstmann-Straussler Disease, Cystic Fibrosis, Huntington’s Disease 
and acute myeloid Leukemia brought about by KRAS. Gerstmann-Straussler disease is a 
prion disease that affects the nervous system and includes ataxia, cognitive dysfunction and 
spasticity. Symptoms develop around the ages of 35 to 50 and patients usually live an average 
of 5 years after diagnosis72. The PRNP gene is associated with this disease as well as 
Creutzfeldt-Jakob disease and a Huntington-like disease. PRNP encodes for a glycoprotein 
that is attached to the plasma membrane. The functional form of this protein has a large 
alpha-helical structure and the pathogenic isoform in beta-pleated sheets73.  
Cystic Fibrosis (CFTR) Cystic Fibrosis is associated primarily with the CFTR gene 
which encodes for an ATP-binding cassette and is involved in chloride ion channels. 
Characteristics of this disease include buildup of mucus in the lungs and digestive problems. 
Symptoms are present from birth and modern medical advancements have allowed patients 
with Cystic Fibrosis to live into adulthood74.  The severity of the disease is likely influenced 
by the presence of mutations in other genes.  
Huntington’s Disease (HTT) Another severe disease that develops well into adulthood 
is Huntington’s disease which is brought about by mutations in the HTT gene. HTT encodes 
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for huntingtin which is a nuclear protein that regulates transcription factors. There is a CAG 
repeat that is often found within Huntington’s patients and the disease seems to have a gain-
of-function aspect to it where the encoded mRNA or resulting protein have a new property 
or express inappropriately.75 Symptoms of this disease include loss of motor function, 
emotional capabilities and intellectual abilities; and eventually leads to death. This disease is 
autosomal dominant so it is likely that a patient whose parent is a carrier of the disease has a 
50% chance of obtaining the mutated carrier gene.76 
Acute Myeloid Leukemia (KRAS) The last gene recommended was KRAS in 
association with acute myeloid Leukemia. Mutations in KRAS are associated with many 
different types of cancers so this gene increases cancer susceptibility. This type of leukemia is 
adult onset and causes bone marrow to produce abnormal myoblasts. KRAS encodes for a 
protein involved in tissue signaling and play a role in proliferation, differentiation and 
senescence. Mutated forms of KRAS are prolific oncogenes that have been associated bladder, 
breast, gastric and lung cancers as well as Noonan syndrome and acute myeloid leukemia. 
The inheritance pattern for acute myeloid leukemia is known to be autosomal dominant 
while for other cancers the inheritance in not known. The severity of all of these diseases 
and the fact that they are adult-onset or can be are reason to include mutations of these 
genes in secondary findings reports.  
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Conclusion 
The goal of this thesis is to convince institutions, and especially the Rare Genomics 
Institute, to implement policies of providing patients with reports on secondary findings. In 
having the ability to easily provide more information to patients but neglecting to do so, 
institutions and medical professionals are doing a disservice to their patients. We are morally 
obligated to act in the greatest beneficent capacity that we can as medical professionals. 
Giving patients as much knowledge about their own body as possible is acting in the most 
beneficent way because patients have the autonomy to do what they will with that 
information. Secondary findings should be encouraged and offered to all patients who 
undergo genetic testing. Information is power and patients gain more power over their 
situation when they know what they can experience. Federal laws like the Genetic 
Information Nondiscrimination Act is at the lowest limit of what is acceptable protection for 
individuals. Further protections for patients are needed but the information that is gathered 
from secondary findings reports are invaluable just the same.  
The general consensus amongst the literature is that secondary findings should be 
reported and part of this report uses RG as an example of how to approach the issue with 
patients. Because RG does not currently deal with secondary findings it may be a rough 
transition to beginning to offer them. Cases that are currently being worked on would likely 
receive secondary findings later than their analysis report but even these liminal state cases 
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should be offered secondary findings. Cases that have already been closed should also be 
offered reanalysis of their genetic data because oftentimes the institution still has the data 
and the contact information of the patient. The speed of transition could affect whether some 
patients are offered the secondary findings report in a timely manner. Filters in databases or 
during sequencing will speed up the process tremendously and there are already some filters 
for the ACMG list like in Omicia Opal.  
More problematic genes can be expected to show up on this list of secondary findings 
from the work that’s being done on monogenic disorders around the world. Reported genes 
may expand to well understood polygenic disorders within the next few decades and the role 
of unknown elements like introns could be determined and included. I hope to continue 
research that contributes to the understanding of hereditary diseases. There is much more 
work to be done before finalizing the list of what should be given to patients. The factors of 
time, cost and availability of genetic sequencing contribute to the growth and use of genetic 
data in diagnosing diseases in contemporary medical practices. The future of genetic analysis 
is looking promising and institutions like Rare Genomics need to be using this technology to 
their best ability and providing secondary findings to patients to fulfill their express purpose 
of helping those in need. 
 
 
 
  
68 
 
Bibliography 
Abitbol, Marc, Christian Menini, Anne-Lise Delezoide, Thomas Rhyner, Michel Vekemans, and 
Jacques Mallet. “Nucleus Basalis Magnocellularis and Hippocampus Are the Major Sites of 
FMR-1 Expression in the Human Fetal Brain.” Nature Genetics 4, no. 2 (June 1993): 147–
53. doi:10.1038/ng0693-147. 
“ACTA2 Actin, Alpha 2, Smooth Muscle, Aorta.” NCBI. Accessed March 11, 2016. 
http://www.ncbi.nlm.nih.gov/gtr/genes/59/. 
“All About The Human Genome Project (HGP).” National Human Genome Research Institute, 
2015. https://www.genome.gov/10001772. 
Appelbaum, Paul S., Erik Parens, Cameron R. Waldman, Robert Klitzman, Abby Fyer, Josue 
Martinez, W. Nicholson Price, and Wendy K. Chung. “Models of Consent to Return of 
Incidental Findings in Genomic Research.” Hastings Center Report 44, no. 4 (2014): 22–32. 
doi:10.1002/hast.328. 
“An Introduction to Next-Generation Sequencing Technology.” 2016. 
http://www.illumina.com/content/dam/illumina-
marketing/documents/products/illumina_sequencing_introduction.pdf. 
“An Overview of the Human Genome Project.” National Human Genome Research Institute. 
2015. https://www.genome.gov/12011238. 
“Bang v. Charles T. Miller Hospital Case Brief,” 2014. 
http://www.lawschoolcasebriefs.net/2014/01/bang-v-charles-t-miller-hospital-case.html. 
Beauchamp, Tom L., and James F. Childress. Principles of Biomedical Ethics: Fifth Edition. 
Oxford University Press, 2001. 
Bengtsson, Luiza, and Henning Otto. “LUMA Interacts with Emerin and Influences Its 
Distribution at the Inner Nuclear Membrane.” Journal of Cell Science 4, no. 124 (2007): 
538–46. doi:10.1242/jcs.019281. 
Bocchini, Carol A. “IDURONATE 2-SULFATASE; IDS.” OMIM, 2010. 
http://www.omim.org/entry/300823?search=IDS&highlight=ids. 
Clarke, Angus J. “Managing the Ethical Challenges of Next Generation Sequencing in Genomic 
Medicine.” British Medical Bulletin 111, no. 1 (2014): 17–30. doi:10.1093/bmb/ldu017 
“Cystic Fibrosis.” US National Library of Medicine, National Institutes of Health, Department of 
Health & Human Services, 2016. https://ghr.nlm.nih.gov/condition/cystic-fibrosis. 
69 
 
“Donate Directly to Rare Genomics Patients.” Rare Genomics Institute, 2016. 
http://www.raregenomics.org/patient-donations/. 
“Franklin, Watson &amp; Crick.” 2010. 
http://virtuallaboratory.colorado.edu/Biofundamentals/labs/WhatisScience/section_08.html. 
“Genetic Discrimination and Other Laws.” National Human Genome Research Institute, 2014. 
https://www.genome.gov/10002077#al-3. 
“GENOMIC DATA SHARING (GDS) Home.” U.S.Department of Health & Human Services. 
Accessed February 14, 2016. https://gds.nih.gov/03policy2.html. 
Guo, Dong-Chuan, Hariyadarshi Pannu, Van Tran-Fadulu, Christina L Papke, Robert K Yu, Nili 
Avidan, Scott Bourgeois, et al. “Mutations in Smooth Muscle α-Actin (ACTA2) Lead to 
Thoracic Aortic Aneurysms and Dissections.” Nature Genetics 39, no. 12 (December 11, 
2007): 1488–93. doi:10.1038/ng.2007.6. 
Gurwitz, David, Isabel Fortier, Jeantine E Lunshof, and Bartha Maria Knoppers. “Children and 
Population Biobanks.” Science 325, no. August (2009): 818–19. 
doi:10.1126/science.1173284. 
Hartz, Patricia A. “DYSTROPHIN; DMD,” 2016. 
http://www.omim.org/entry/300377?search=DMD&highlight=dmd 
Hershberger, Patricia E, Catherine Schoenfeld, and Ilan Tur-Kaspa. “Unraveling Preimplantation 
Genetic Diagnosis for High-Risk Couples: Implications for Nurses at the Front Line of 
Care.” Nursing for Women’s Health 15, no. 1 (2011): 36–45. doi:10.1111/j.1751-
486X.2011.01609.x. 
“How We Help Patients.” Rare Genomics Institute, 2016. http://www.raregenomics.org/process/. 
“Huntington Disease.” U.S National Library of Medicine. Accessed March 29, 2016. 
http://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0024706/. 
“Incontinentia Pigmenti.” National Institutes of Health. US National Library of Medicine, 
National Institutes of Health, Department of Health & Human Services, 2008. 
https://ghr.nlm.nih.gov/condition/incontinentia-pigmenti. 
Institute, Rare Genomics. “Authorization for The Release of Medical Information,” n.d. 
Klitzman, R, P S Appelbaum, A Fyer, J Martinez, B Buquez, J Wynn, C R Waldman, J Phelan, E 
Parens, and W K Chung.. “Researchers’ Views on Return of Incidental Genomic Research 
Results: Qualitative and Quantitative Findings.” Genet Med 15 (11)(2013): 888–95. 
doi:10.1038/gim.2013.87. 
70 
 
Kniffen, Cassandra L., and Victor A. McKusick. “ORNITHINE 
CARBAMOYLTRANSFERASE; OTC,” 2006. 
http://www.omim.org/entry/300461?search=OTC&highlight=otc. 
Lunshof JE, and Ball MP. “Our Genomes Today: Time to Be Clear,” 2013. doi:10.1186/gm52. 
Liu, P. Paul, Lucio H. Castilla, Lisa Garrett, Neeraj Adya, Donald Orlic, Amalia Dutra, Stacie 
Anderson, Jennie Owens, Michael Eckhaus, and David Bodine. “The Fusion Gene Cbfb-
MYH11 Blocks Myeloid Differentiation and Predisposes Mice to Acute Myelomonocytic 
Leukaemia.” Nature Genetics 23, no. 2 (October 1, 1999): 144–46. doi:10.1038/13776. 
Mastrianni, James A. Genetic Prion Diseases. GeneReviews(®). University of Washington, 
Seattle, 1993. http://www.ncbi.nlm.nih.gov/pubmed/20301407. 
MacDonald, Marcy E., Christine M. Ambrose, Mabel P. Duyao, Richard H. Myers, Carol Lin, 
Lakshmi Srinidhi, Glenn Barnes, et al. “A Novel Gene Containing a Trinucleotide Repeat 
That Is Expanded and Unstable on Huntington’s Disease Chromosomes.” Cell 72, no. 6 
(1993): 971–83. doi:10.1016/0092-8674(93)90585-E 
McKusick, Victor A., and Ada Hamosh. “ATR-X GENE; ATRX.” OMIM, 2016. 
http://www.omim.org/entry/300032?search=ATRX&highlight=atrx. 
McKusick, Victor A., and Ada Hamosh. “BREAST CANCER 1 GENE; BRCA1.” OMIM, 2016.  
http://www.omim.org/entry/113705?search=BRCA1&highlight=brca1. 
 
McKusick, Victor A., and Ada Hamosh. “BRCA2 GENE; BRCA2.” OMIM, 2016. 
http://www.omim.org/entry/600185?search=BRCA2&highlight=brca2. 
McKusick, Victor A., and Paul J. Converse. “DESMOGLEIN 2; DSG2.” OMIM, 2011. 
http://www.omim.org/entry/125671?search=DSG2&highlight=dsg2. 
McKusick, Victor A., and Marla J. F. O’Neill. “DESMOCOLLIN 2; DSC2.” OMIM, 2012. 
http://www.omim.org/entry/125645?search=DSC2&highlight=dsc2. 
Meindl, Alfons, Wolfgang Berger, Thomas Meitinger, Dorien van de Pol, Helene Achatz, 
Christa Dörner, Martina Haasemann, et al. “Norrie Disease Is Caused by Mutations in an 
Extracellular Protein Resembling C–terminal Globular Domain of Mucins.” Nature 
Genetics 2, no. 2 (October 1992): 139–43. doi:10.1038/ng1092-139. 
Morozova, Olena, and Marco A. Marra. “Applications of Next-Generation Sequencing 
Technologies in Functional Genomics.” Genomics 92, no. 5 (2008): 255–64. 
doi:10.1016/j.ygeno.2008.07.001. 
“Mucopolysaccharidosis Type II.” US National Library of Medicine, National Institutes of 
Health, Department of Health & Human Services, 2016. 
https://ghr.nlm.nih.gov/condition/mucopolysaccharidosis-type-ii. 
71 
 
OHRP, and DHHS. “Guidance on the Genetic Information Nondiscrimination Act : Implications 
for Investigators and Institutional Review Boards” March 24 2 (2009): 7. 
Olson, S, S H Beachy, C F Giammaria, and A C Berger. Integrating Large-Scale Genomic 
Information Into Clinical Practice: Workshop Summary, 2012. 
O’Neill, Marla J. F. “DESMOPLAKIN; DSP.” OMIM, 2015. 
http://www.omim.org/entry/125647?search=DSP &highlight=dsp. 
O’Neill, Marla J. F., and Patti M. Sherman. “PLAKOPHILIN 2; PKP2.” OMIM, 2008. 
http://www.omim.org/entry/602861?search=PKP2&highlight=pkp2. 
 
Picketts, D J, D R Higgs, S Bachoo, D J Blake, O W Quarrell, and R J Gibbons. “ATRX Encodes 
a Novel Member of the SNF2 Family of Proteins: Mutations Point to a Common 
Mechanism Underlying the ATR-X Syndrome.” Human Molecular Genetics 5, no. 12 
(1996): 1899–1907. doi:6d0165 [pii]. 
Simon, Christian M., Laura Shinkunas, Debra Brandt, and Janet K. Williams. “Individual Genetic 
and Genomic Research Results and the Tradition of Informed Consent: Exploring U.S. 
Review Board Guidance” 38, no. 7 (2012): 417–22. doi:10.1136/medethics-2011-100273. 
“Timeline: History of Genomics.” Wellcome Genome Campus. 2016. 
http://www.yourgenome.org/facts/timeline-history-of-genomics. 
U.S. Department of Health and Human Services, Food and Drug Administration, Office of Good 
Clinical Practice, Center for Drug Evaluation and Research, Center for Biologics Evaluation 
and Research, and Center for Devices and Radiological Health. “Informed Consent 
Information Sheet Guidance for IRBs, Clinical Investigators, and Sponsors,” 2014. 
“Wiskott-Aldrich Syndrome in Children.” Boston Children’s Hospital. Accessed March 29, 
2016. http://www.childrenshospital.org/conditions-and-treatments/conditions/w/wiskott-
aldrich-syndrome. 
Wang, Li, Dong-Chuan Guo, Jiumei Cao, Limin Gong, Kristine E Kamm, Ellen Regalado, Li Li, 
et al. “Mutations in Myosin Light Chain Kinase Cause Familial Aortic Dissections.” The 
American Journal of Human Genetics 87 (2010): 701–7. doi:10.1016/j.ajhg.2010.10.006. 
Wolf, Susan M, Brittney N Crock, Brian Van Ness, Frances Lawrenz, Jeffrey P Kahn, Laura M 
Beskow, Mildred K Cho, et al. “Managing Incidental Findings and Research Results in 
Genomic Research Involving Biobanks and Archived Data Sets.” Genetics in Medicine : 
Official Journal of the American College of Medical Genetics 14, no. 4 (April 2012): 361–
84. doi:10.1038/gim.2012.23. 
Wraith, J. Edmond, Maurizio Scarpa, Michael Beck, Olaf A. Bodamer, Linda De Meirleir, 
Nathalie Guffon, Allan Meldgaard Lund, Gunilla Malm, Ans T. Van der Ploeg, and Jiri 
Zeman. “Mucopolysaccharidosis Type II (Hunter Syndrome): A Clinical Review and 
72 
 
Recommendations for Treatment in the Era of Enzyme Replacement Therapy.” European 
Journal of Pediatrics 167 (3)(2008): 267–77. doi:10.1007/s00431-007-0635-4. 
Vanik, D. L., and W. K. Surewicz. “Disease-Associated F198S Mutation Increases the 
Propensity of the Recombinant Prion Protein for Conformational Conversion to Scrapie-like 
Form.” Journal of Biological Chemistry 277, no. 50 (December 13, 2002): 49065–70. 
doi:10.1074/jbc.M207511200. 
Zonana, Jonathan, Melissa E. Elder, Lynda C. Schneider, Seth J. Orlow, Celia Moss, Mahin 
Golabi, Stuart K. Shapira, et al. “A Novel X-Linked Disorder of Immune Deficiency and 
Hypohidrotic Ectodermal Dysplasia Is Allelic to Incontinentia Pigmenti and Due to 
Mutations in IKK-Gamma (NEMO).” The American Journal of Human Genetics. Vol. 67, 
2000. doi:10.1086/316914. 
 
 
 
